siRNA targeting angiotensinogen and its pharmaceutical uses
SiRNAs targeting AGT with specific modifications provide a novel approach to inhibit AGT synthesis, overcoming the limitations of current antihypertensive drugs by effectively reducing angiotensin II levels and controlling hypertension.
Patent Information
- Application Number
- JP2024529385
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-05-20
- Filing Date
- 2022-11-18
- Publication Date
- 2024-11-11
AI Technical Summary
Current antihypertensive drugs are ineffective for more than two-thirds of hypertension patients, leading to uncontrolled blood pressure and compliance issues due to side effects, while conventional small molecule drugs and large biological molecules fail to target 80% of undruggable proteins, including angiotensinogen (AGT), the upstream precursor in the renin-angiotensin system.
Development of siRNAs targeting angiotensinogen (AGT) with specific sense and antisense strands, including modifications and overhangs, to mediate RNA interference and inhibit AGT synthesis, thereby reducing angiotensin II levels.
The siRNAs effectively reduce AGT protein levels, providing sustained antihypertensive effects by inhibiting AGT synthesis, addressing the limitations of existing drugs and targeting undruggable proteins.
Smart Images

Figure 2024541713000220 
Figure 2024541713000221 
Figure 2024541713000001
Abstract
Description
[Technical field]
[0001] This disclosure claims priority to Chinese patent application CN202111398206.0 filed on November 19, 2021, priority to Chinese patent application CN202111542323.X filed on December 16, 2021, and priority to Chinese patent application CN202210554195.9 filed on May 20, 2022, and this disclosure cites the above Chinese patent applications in their entirety.
[0002] The present disclosure relates to siRNAs, double-stranded ribonucleic acid (dsRNA), complexes, and uses thereof that target angiotensinogen (AGT). [Background technology]
[0003] AGT is also called SERPINA8 or ANHU. AGT is encoded by the AGT gene, which is mainly produced by the liver, and is the rate-limiting substrate of the renin-angiotensin system (RAS) and the precursor of angiotensin peptides. Under the action of active renin in plasma, AGT is cleaved to angiotensin I, which is then converted to angiotensin II by the action of angiotensin-converting enzyme (ACE), which is circulating and locally expressed. Meanwhile, angiotensin II is the most major biologically active substance in the renin-angiotensin-aldosterone system (RAAS), and plays an important role in biological blood pressure regulation, since it brings about arterial vasoconstriction and secretion of adrenal cortical aldosterone through binding to angiotensin II type 1 receptor (AT1R). When angiotensin II is produced in excess or AT1R is stimulated excessively, the RAAS system is impaired, causing hypertension. Many studies have shown that AGT gene polymorphisms are closely associated with the body's blood pressure regulation ability, and association studies in the Chinese Han population have shown that the AGT M235T site polymorphism is associated with the development of essential hypertension (ER).
[0004] Hypertension is a common cardiovascular disease worldwide, with a high global prevalence of 10%-20%, and may lead to cerebrovascular, cardiac and renal complications, and is a major risk factor for various diseases, disorders and conditions (e.g., stroke, coronary heart disease, chronic kidney disease, myocardial infarction, heart failure, aneurysm, peripheral arterial disease, cardiac injury and other cardiovascular-related diseases). Currently, there are five main types of drugs for treating hypertension, including diuretics, beta-receptor blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Although there are many types of antihypertensive drugs available for the treatment of hypertension, more than two-thirds of subjects cannot be controlled with one type of antihypertensive drug and require two or more different types of antihypertensive drugs. Compliance and side effects increase with the use of drugs, further reducing the number of subjects whose blood pressure is controlled.
[0005] RNA interference RNAi is an efficient method to express silent genes, which can specifically degrade target gene mRNA by post-transcriptional regulatory mechanism. According to statistics, more than 80% of disease-related proteins are currently unable to be targeted by conventional small molecule drugs and biological macromolecule drugs, and belong to undruggable proteins. As the most upstream precursor in RAAS, AGT has already demonstrated its cascade effect in blood pressure regulation, and inhibiting the synthesis of AGT in the liver can lead to a sustained reduction in AGT protein, which can ultimately lead to a sustained reduction in the vasoconstrictor AngII, and its inhibitory effect has good antihypertensive effect. Summary of the Invention
[0006] The present disclosure provides siRNAs targeting angiotensinogen (AGT).
[0007] In some embodiments, the disclosure provides siRNAs comprising a sense strand and an antisense strand that form a double-stranded region.
[0008] the sense strand comprises a sequence that differs from any one of the nucleotide sequences of SEQ ID NO:1 to SEQ ID NO:6 by 3 or less (e.g., 0, 1, 2, or 3) nucleotides, and comprises at least 15 (e.g., 16, 17, 18, 19, 20, or 21) consecutive nucleotides; The antisense strand contains a sequence that differs from any one of the nucleotide sequences of SEQ ID NO:7 to SEQ ID NO:12 by three or less nucleotides (e.g., 0, 1, 2, or 3), and contains at least 15 (e.g., 16, 17, 18, 19, 20, or 21) consecutive nucleotides.
[0009] In some embodiments, antisense strand is at least partially reverse-complementary to target sequence to mediate RNA interference.In some embodiments, there are 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less mismatches between antisense strand and target sequence.In some embodiments, antisense strand is completely reverse-complementary to target sequence.
[0010] In some embodiments, the sense strand is at least partially reverse-complementary to the antisense strand to form a double-stranded region.In some embodiments, there are 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less mismatches between the sense strand and the antisense strand.In some embodiments, the sense strand is completely reverse-complementary to the antisense strand.
[0011] In some embodiments, the siRNA of the present disclosure comprises one or two blunt ends.
[0012] In some specific embodiments, each strand of the siRNA independently contains 1 to 2 unpaired nucleotides.
[0013] In some embodiments, the siRNA of the present disclosure comprises an overhang located at the 3' end of the siRNA antisense strand.
[0014] In some embodiments, the sense strand and the antisense strand each independently have 16 to 35, 16 to 34, 17 to 34, 17 to 33, 18 to 33, 18 to 32, 18 to 31, 18 to 30, 18 to 29, 18 to 28, 18 to 27, 18 to 26, 18 to 25, 18 to 24, 18 to 23, 19 to 25, 19 to 24, or 19 to 23 nucleotides.
[0015] In some embodiments, the lengths of the sense strand and the antisense strand are the same or different, the sense strand being 19-23 nucleotides in length and the antisense strand being 19-26 nucleotides in length. The length ratio of the sense strand to the antisense strand of the siRNA provided by the present disclosure may be 19 / 19, 19 / 20, 19 / 21, 19 / 22, 19 / 23, 19 / 24, 19 / 25, 19 / 26, 20 / 19, 20 / 20, 20 / 21, 20 / 22, 20 / 23, 20 / 24, 20 / 25, 20 / 26, 21 / 20, 21 / 21, 21 / 22, 21 / 23, 21 / 24, 21 / 25, 21 / 26, 22 / 20, 22 / 21, 22 / 22, 22 / 23, 22 / 24, 22 / 25, 22 / 26, 23 / 20, 23 / 21, 23 / 22, 23 / 23, 23 / 24, 23 / 25, or 23 / 26. In some embodiments, the length ratio of the sense strand to the antisense strand of the siRNA is 19 / 21, 21 / 23, or 23 / 25. In some embodiments, the length ratio of the sense strand to the antisense strand of the siRNA is 19 / 21.
[0016] In some embodiments, the sense strand comprises at least 15 consecutive nucleotides and has no more than two nucleotide differences from any one of SEQ ID NOs: 1 to 6. In some embodiments, the sense strand has no more than one nucleotide difference from the nucleotide sequence, and in some embodiments, has one nucleotide difference. In some embodiments, the antisense strand comprises at least 15 consecutive nucleotides and has no more than two nucleotide differences from the nucleotide sequence of SEQ ID NO:7 to SEQ ID NO:12, in some embodiments, has no more than one nucleotide difference from the nucleotide sequence, and in some embodiments, has one nucleotide difference.
[0017] In some embodiments, the sense strand comprises at least 15 contiguous nucleotides of the nucleotide sequence of any one of SEQ ID NO:1 to SEQ ID NO:6. In some embodiments, the sense strand comprises at least 16 contiguous nucleotides of the nucleotide sequence of any one of SEQ ID NO:1 to SEQ ID NO:6. In some embodiments, the sense strand comprises at least 18 contiguous nucleotides of the nucleotide sequence of any one of SEQ ID NO:1 to SEQ ID NO:6. In some embodiments, the sense strand comprises at least 19 contiguous nucleotides of the nucleotide sequence of any one of SEQ ID NO:1 to SEQ ID NO:6.
[0018] In some embodiments, the antisense strand comprises at least 15 contiguous nucleotides of any one of the nucleotide sequences of SEQ ID NO:7 to SEQ ID NO:12. In some embodiments, the antisense strand comprises at least 18 contiguous nucleotides of any one of the nucleotide sequences of SEQ ID NO:7 to SEQ ID NO:12. In some embodiments, the antisense strand comprises at least 19 contiguous nucleotides of any one of the nucleotide sequences of SEQ ID NO:7 to SEQ ID NO:12. In some embodiments, the antisense strand comprises at least 20 contiguous nucleotides of any one of the nucleotide sequences of SEQ ID NO:7 to SEQ ID NO:12. In some embodiments, the antisense strand comprises at least 21 contiguous nucleotides of any one of the nucleotide sequences of SEQ ID NO:7 to SEQ ID NO:12.
[0019] In some embodiments, the sense strand comprises a nucleotide sequence selected from SEQ ID NO:1 to SEQ ID NO:6.
[0020] In some embodiments, the antisense strand comprises a nucleotide sequence selected from SEQ ID NO:7 to SEQ ID NO:12.
[0021] In some embodiments, at least one nucleotide in each of the sense strand and the antisense strand of the present disclosure is a modified nucleotide.In some embodiments, all nucleotides of the sense strand and all nucleotides of the antisense strand described in the present disclosure are modified nucleotides.
[0022] The present disclosure provides siRNAs comprising a sense strand and an antisense strand that form a double-stranded region.
[0023] The sense strand comprises a sequence which differs from any one of the nucleotide sequences of SEQ ID NO:1 to SEQ ID NO:6 by 3 or less nucleotides and comprises at least 15 consecutive nucleotides, the antisense strand comprises a sequence which differs from any one of the nucleotide sequences of SEQ ID NO:7 to SEQ ID NO:12 by 3 or less nucleotides and comprises at least 15 consecutive nucleotides, and at least one nucleotide at positions 2 to 8 (e.g., positions 2, 3, 4, 5, 6, 7, and 8) of the 5' region of the antisense strand comprises a 2'-methoxy modification, or a chemical modification shown in Formula (I) or a tautomer modification thereof.
[0024] Formula (I) is [ka] Selected from wherein Y is selected from O, NH and S; each X is independently selected from CR4(R4'), S, NR5, and NH-CO, wherein R4, R4', and R5 are each independently H or a C1-C6 alkyl group; J2 is H or a C1-C6 alkyl group; n=0, 1 or 2, m=0, 1 or 2, s=0 or 1; R3 is H, OH, halogen, NH2, C1-C6 alkyl group, C1-C6 alkoxy group, C2-C6 alkenyl group, C2-C6 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) p R6, wherein R6 is selected from OH, halogen, a methoxy group, an ethoxy group, N3, a C2-C6 alkenyl group, and a C2-C6 alkynyl group, and p=1, 2, or 3; Q1 is [ka] , Q2 is R2, or Q1 is R2, Q2 is [ka] and Among them, R1 is H, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, or (CH2) q R7, wherein R7 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C6 alkenyl and C2-C6 alkynyl, and q=1, 2 or 3; J1 is H or a C1-C6 alkyl group; R2 is H, OH, halogen, NH2, C1-C6 alkyl group, C1-C6 alkoxy group, C2-C6 alkenyl group, C2-C6 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) r R8, wherein R8 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C6 alkenyl and C2-C6 alkynyl, and r=1, 2 or 3; Optionally, R1 and R2 are directly linked to form a ring; B is a base, Among them, the chemical modification shown in the above formula (I) or its tautomer modification is [ka] isn't it.
[0025] In some embodiments, when X is NH-CO, R1 is not H.
[0026] In some embodiments, B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0027] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0028] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0029] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0030] In some embodiments, formula (I) is selected from formula (I-1):
[0031] [ka] Among them, Y is selected from O, NH and S; each X is independently selected from CR4(R4'), S, NR5, and NH-CO, wherein R4, R4', and R5 are each independently H or a C1-C6 alkyl group; Each J1, J2 is independently H or a C1-C6 alkyl group; n=0, 1 or 2, m=0, 1 or 2, s=0 or 1; R3 is H, OH, halogen, NH2, C1-C6 alkyl group, C1-C6 alkoxy group, C2-C6 alkenyl group, C2-C6 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) p R6, wherein R6 is selected from OH, halogen, a methoxy group, an ethoxy group, N3, a C2-C6 alkenyl group, and a C2-C6 alkynyl group, and p=1, 2, or 3; R1 is H, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, or (CH2) q R7, wherein R7 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C6 alkenyl and C2-C6 alkynyl, and q=1, 2 or 3; R2 is H, OH, halogen, NH2, C1-C6 alkyl group, C1-C6 alkoxy group, C2-C6 alkenyl group, C2-C6 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) r R8, wherein R8 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C6 alkenyl and C2-C6 alkynyl, and r=1, 2 or 3; Optionally, R1 and R2 are directly linked to form a ring; B is as defined in formula (I).
[0032] In some embodiments of formula (I-1), B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0033] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0034] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0035] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0036] In some embodiments, formula (I) is selected from formula (I-2).
[0037] [ka] Among them, Y is selected from O, NH and S, each X is independently selected from CR4(R4'), S, NR5, and NH-CO, wherein R4, R4', and R5 are each independently H or a C1-C6 alkyl group; n=0, 1 or 2, m=0, 1 or 2, s=0 or 1; Each J1, J2 is independently H or a C1-C6 alkyl group; R3 is H, OH, halogen, NH2, C1-C6 alkyl group, C1-C6 alkoxy group, C2-C6 alkenyl group, C2-C6 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) pR6, wherein R6 is selected from OH, halogen, a methoxy group, an ethoxy group, N3, a C2-C6 alkenyl group, and a C2-C6 alkynyl group, and p=1, 2, or 3; R1 is H, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, or (CH2) q R7, wherein R7 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C6 alkenyl and C2-C6 alkynyl, and q=1, 2 or 3; R2 is H, a C1-C6 alkyl group, a C1-C6 alkoxy group, S-CH3, NCH3(CH3), OCH2CH2OCH3, an -O-alkylamino group, and (CH2) r R8, wherein R8 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C6 alkenyl and C2-C6 alkynyl, and r=1, 2 or 3; Optionally, R1 and R2 are directly linked to form a ring; B is as defined in formula (I).
[0038] In some embodiments of formula (I-2), B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0039] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0040] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0041] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0042] In some embodiments, the chemical modification or tautomer modification thereof is [ka] isn't it.
[0043] In some embodiments, each X is independently selected from CR4(R4'), S, NR5, and NH-CO, wherein R4, R4', and R5 are each independently H or a C1-C3 alkyl group; n=0, 1 or 2, m=0, 1 or 2, s=0 or 1; Each J1 and J2 is independently H or a C1-C3 alkyl group; R3 is H, OH, halogen, NH2, C1-C3 alkyl group, C1-C3 alkoxy group, C2-C4 alkenyl group, C2-C4 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) p R6, wherein R6 is selected from OH, halogen, a methoxy group, an ethoxy group, N3, a C2-C6 alkenyl group, and a C2-C6 alkynyl group, and p=1, 2, or 3; R1 is H, a C1-C3 alkyl group, a C1-C3 alkoxy group, a C2-C4 alkenyl group, a C2-C4 alkynyl group, or (CH2) q R7, wherein R7 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C4 alkenyl and C2-C4 alkynyl, and q=1, 2 or 3; R2 is H, OH, halogen, NH2, C1-C3 alkyl group, C1-C3 alkoxy group, C2-C4 alkenyl group, C2-C4 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) r R8, wherein R8 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C4 alkenyl and C2-C4 alkynyl, and r=1, 2 or 3; Optionally, R1 and R2 are directly linked to form a ring.
[0044] B is as defined in formula (I).
[0045] In some embodiments, B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0046] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0047] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0048] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0049] In some embodiments, each X is independently selected from CR4(R4'), S, NR5, and NH-CO, wherein R4, R4', and R5 are each independently H, a methyl group, an ethyl group, an n-propyl group, or an isopropyl group; n=0, 1 or 2, m=0, 1 or 2, s=0 or 1; Each of J1 and J2 is independently H or a methyl group; R3 is H, OH, F, Cl, NH2, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, vinyl, allyl, ethynyl, propargyl, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-methylamino, -O-ethylamino, and (CH2). p R6, wherein R6 is selected from OH, F, Cl, a methoxy group, an ethoxy group, N3, a vinyl group, an allyl group, an ethynyl group, and a propargyl group, and p=1 or 2; R1 is H, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, vinyl, allyl, ethynyl, propargyl, or (CH2) q R7, wherein R7 is selected from OH, F, Cl, methoxy, ethoxy, N3, vinyl, allyl, ethynyl and propargyl, and q=1 or 2; R2 is H, OH, F, Cl, NH2, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, vinyl, allyl, ethynyl, propargyl, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-methylamino, -O-ethylamino, and (CH2). r R8, wherein R8 is selected from OH, F, Cl, methoxy, ethoxy, N3, vinyl, allyl, ethynyl and propargyl, and r=1 or 2; Optionally, R1 and R2 are directly linked to form a ring.
[0050] B is as defined in formula (I).
[0051] In some embodiments, B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0052] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0053] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0054] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0055] B is as defined in formula (I).
[0056] In some embodiments, B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, and 3-nitropyrrole.
[0057] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0058] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0059] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0060] In some embodiments, Y is O or NH; and each X is independently selected from NH—CO, CH, and NH; n=0 or 1, m=0 or 1, s=0 or 1, Each J1 and J2 is independently H; R1 is selected from H, a methyl group, and CH2OH; R2 is selected from H, OH, NH2, a methyl group, and CH2OH; R3 is selected from H, OH, NH2, a methyl group, and CH2OH; Optionally, R1 and R2 are directly linked to form a ring; B is as defined in formula (I).
[0061] In some embodiments, B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0062] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0063] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0064] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0065] In some embodiments, Y is O or NH; and each X is independently selected from NH—CO, CH, and NH; n=0 or 1, m=0 or 1, s=0 or 1, Each J1 and J2 is independently H; R1 is selected from H, a methyl group, and CH2OH; R2 is selected from H, a methyl group, and CH2OH; R3 is selected from H, OH, NH2, a methyl group, and CH2OH; Optionally, R1 and R2 are directly linked to form a ring.
[0066] In some embodiments, B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0067] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0068] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0069] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0070] In some embodiments, the chemical modification shown in formula (I) above or a tautomer modification thereof is [ka] Selected from Among them, B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0071] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0072] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0073] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0074] In some embodiments, the chemical modification shown in formula (I) above or a tautomeric modification thereof is [ka] wherein B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0075] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0076] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0077] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0078] In some embodiments, the chemical modification shown in formula (I) or a tautomeric modification thereof is [ka] Selected from Wherein, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole and 3-nitropyrrole.
[0079] In some embodiments, B is a base at a position corresponding to positions 2 to 8 of the 5' region of the antisense strand.
[0080] In some embodiments, when the chemical modification shown in formula (I) or a tautomer modification thereof is at the 5th position of the 5' region, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole. In some embodiments, B is the base at the position corresponding to the 5th position of the 5' region of the antisense strand.
[0081] In some embodiments, when the chemical modification shown in formula (I) or its tautomer modification is at position 6 of the 5' region, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole. In some embodiments, B is the base at the position corresponding to position 6 of the 5' region of the antisense strand.
[0082] In some embodiments, when the chemical modification shown in formula (I) or a tautomer modification thereof is at position 7 of the 5' region, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole. In some embodiments, B is the base at the position corresponding to position 7 of the 5' region of the antisense strand.
[0083] In some embodiments, the nucleotide comprising the chemical modification according to formula (I) or a tautomeric modification thereof is a nucleotide comprising the chemical modification according to formula (I') or a tautomeric modification thereof: [ka] wherein Y is selected from O, NH and S; each X is independently selected from CR4(R4'), S, NR5, and NH-CO, wherein R4, R4', and R5 are each independently H or a C1-C6 alkyl group; J2 is H or a C1-C6 alkyl group; n=0, 1 or 2, m=0, 1 or 2, s=0 or 1; R3 is H, OH, halogen, NH2, C1-C6 alkyl group, C1-C6 alkoxy group, C2-C6 alkenyl group, C2-C6 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) p R6, wherein R6 is selected from OH, halogen, a methoxy group, an ethoxy group, N3, a C2-C6 alkenyl group, and a C2-C6 alkynyl group, and p=1, 2, or 3; Q 1’ teeth [ka] , Q 2’ is R2, or Q 1’ R2, Q 2’ teeth [ka] and Among them, R1 is H, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, or (CH2) q R7, wherein R7 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C6 alkenyl and C2-C6 alkynyl, and q=1, 2 or 3; J1 is H or a C1-C6 alkyl group; R2 is H, OH, halogen, NH2, C1-C6 alkyl group, C1-C6 alkoxy group, C2-C6 alkenyl group, C2-C6 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) r R8, wherein R8 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C6 alkenyl and C2-C6 alkynyl, and r=1, 2 or 3; Optionally, R1 and R2 are directly linked to form a ring; B is a base, M is O or S; Among them, the chemical modification shown in the above formula (I') or its tautomer modification is [ka] isn't it.
[0084] In some embodiments, when X is NH-CO, R1 is not H.
[0085] In some embodiments of formula (I'), B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0086] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0087] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0088] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0089] In some embodiments, formula (I') is selected from formula (I'-1).
[0090] [ka] wherein Y is selected from O, NH and S; each X is independently selected from CR4(R4'), S, NR5, and NH-CO, wherein R4, R4', and R5 are each independently H or a C1-C6 alkyl group; Each J1, J2 is independently H or a C1-C6 alkyl group; n=0, 1 or 2, m=0, 1 or 2, s=0 or 1; R3 is H, OH, halogen, NH2, C1-C6 alkyl group, C1-C6 alkoxy group, C2-C6 alkenyl group, C2-C6 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) p R6, wherein R6 is selected from OH, halogen, a methoxy group, an ethoxy group, N3, a C2-C6 alkenyl group, and a C2-C6 alkynyl group, and p=1, 2, or 3; R1 is H, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, or (CH2) q R7, wherein R7 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C6 alkenyl and C2-C6 alkynyl, and q=1, 2 or 3; R2 is H, OH, halogen, NH2, C1-C6 alkyl group, C1-C6 alkoxy group, C2-C6 alkenyl group, C2-C6 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) r R8, wherein R8 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C6 alkenyl and C2-C6 alkynyl, and r=1, 2 or 3; M is O or S; Optionally, R1 and R2 are directly linked to form a ring; B is as defined in formula (I').
[0091] In some embodiments of formula (I'-1), B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0092] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0093] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0094] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0095] In some embodiments, formula (I') is selected from formula (I'-2).
[0096] [ka] wherein Y is selected from O, NH and S; each X is independently selected from CR4(R4'), S, NR5, and NH-CO, wherein R4, R4', and R5 are each independently H or a C1-C6 alkyl group; n=0, 1 or 2, m=0, 1 or 2, s=0 or 1; Each J1, J2 is independently H or a C1-C6 alkyl group; R3 is H, OH, halogen, NH2, C1-C6 alkyl group, C1-C6 alkoxy group, C2-C6 alkenyl group, C2-C6 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) p R6, wherein R6 is selected from OH, halogen, a methoxy group, an ethoxy group, N3, a C2-C6 alkenyl group, and a C2-C6 alkynyl group, and p=1, 2, or 3; R1 is H, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, or (CH2) q R7, wherein R7 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C6 alkenyl and C2-C6 alkynyl, and q=1, 2 or 3; R2 is H, a C1-C6 alkyl group, a C1-C6 alkoxy group, S-CH3, NCH3(CH3), OCH2CH2OCH3, an -O-alkylamino group, and (CH2) r R8, wherein R8 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C6 alkenyl and C2-C6 alkynyl, and r=1, 2 or 3; Optionally, R1 and R2 are directly linked to form a ring; M is O or S; B is as defined in formula (I').
[0097] In some embodiments of formula (I'-2), B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0098] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0099] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0100] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0101] In some embodiments, the chemical modification or tautomer modification thereof is [ka] isn't it.
[0102] In some embodiments, when X is NH-CO, R1 is not H.
[0103] In some embodiments, each X is independently selected from CR4(R4'), S, NR5, and NH-CO, wherein R4, R4', and R5 are each independently H or a C1-C3 alkyl group; n=0, 1 or 2, m=0, 1 or 2, s=0 or 1; Each J1 and J2 is independently H or a C1-C3 alkyl group; R3 is H, OH, halogen, NH2, C1-C3 alkyl group, C1-C3 alkoxy group, C2-C4 alkenyl group, C2-C4 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) p R6, wherein R6 is selected from OH, halogen, a methoxy group, an ethoxy group, N3, a C2-C6 alkenyl group, and a C2-C6 alkynyl group, and p=1, 2, or 3; R1 is H, a C1-C3 alkyl group, a C1-C3 alkoxy group, a C2-C4 alkenyl group, a C2-C4 alkynyl group, or (CH2) q R7, wherein R7 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C4 alkenyl and C2-C4 alkynyl, and q=1, 2 or 3; R2 is H, OH, halogen, NH2, C1-C3 alkyl group, C1-C3 alkoxy group, C2-C4 alkenyl group, C2-C4 alkynyl group, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-alkylamino group and (CH2) r R8, wherein R8 is selected from OH, halogen, methoxy, ethoxy, N3, C2-C4 alkenyl and C2-C4 alkynyl, and r=1, 2 or 3; Optionally, R1 and R2 are directly linked to form a ring.
[0104] In some embodiments, each X is independently selected from CR4(R4'), S, NR5, and NH-CO, wherein R4, R4', and R5 are each independently H, a methyl group, an ethyl group, an n-propyl group, or an isopropyl group; n=0, 1 or 2, m=0, 1 or 2, s=0 or 1; Each of J1 and J2 is independently H or a methyl group; R3 is H, OH, F, Cl, NH2, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, vinyl, allyl, ethynyl, propargyl, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-methylamino, -O-ethylamino, and (CH2). p R6, wherein R6 is selected from OH, F, Cl, a methoxy group, an ethoxy group, N3, a vinyl group, an allyl group, an ethynyl group, and a propargyl group, and p=1 or 2; R1 is H, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, vinyl, allyl, ethynyl, propargyl, or (CH2) q R7, wherein R7 is selected from OH, F, Cl, methoxy, ethoxy, N3, vinyl, allyl, ethynyl and propargyl, and q=1 or 2; R2 is H, OH, F, Cl, NH2, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, vinyl, allyl, ethynyl, propargyl, S-CH3, NCH3(CH3), OCH2CH2OCH3, -O-methylamino, -O-ethylamino, and (CH2). r R8, wherein R8 is selected from OH, F, Cl, methoxy, ethoxy, N3, vinyl, allyl, ethynyl and propargyl, and r=1 or 2; Optionally, R1 and R2 are directly linked to form a ring.
[0105] In some embodiments, B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0106] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0107] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0108] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0109] In some embodiments, Y is O or NH; and each X is independently selected from NH—CO, CH, and NH; n=0 or 1, m=0 or 1, s=0 or 1, Each J1 and J2 is independently H; R1 is selected from H, a methyl group, and CH2OH; R2 is selected from H, OH, NH2, a methyl group, and CH2OH; R3 is selected from H, OH, NH2, a methyl group, and CH2OH; Optionally, R1 and R2 are directly linked to form a ring.
[0110] In some embodiments, B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0111] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0112] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0113] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0114] In some embodiments, Y is O or NH; and each X is independently selected from NH—CO, CH, and NH; n=0 or 1, m=0 or 1, s=0 or 1, Each J1 and J2 is independently H; R1 is selected from H, a methyl group, and CH2OH; R2 is selected from H, a methyl group, and CH2OH; R3 is selected from H, OH, NH2, a methyl group, and CH2OH; Optionally, R1 and R2 are directly linked to form a ring.
[0115] In some embodiments, B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0116] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0117] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0118] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0119] In some embodiments, the chemical modification shown in formula (I') above or a tautomer modification thereof is [ka] [ka] Selected from In which M is O or S; B is as defined in formula (I').
[0120] In some embodiments, B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0121] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0122] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0123] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0124] In some embodiments, the chemical modification shown in formula (I') above or a tautomer modification thereof is [ka] Selected from In which M is O or S; B is as defined in formula (I').
[0125] In some embodiments, B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0126] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0127] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0128] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0129] In some embodiments, the chemical modification shown in formula (I') above or a tautomer modification thereof is [ka] wherein M is O or S; B is as defined in formula (I').
[0130] In some embodiments, B is a base selected from a purine base, a pyrimidine base, indole, 5-nitroindole, 3-nitropyrrole, and the like.
[0131] In some embodiments, B is selected from adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0132] In some embodiments, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole.
[0133] In some embodiments, B is the base at the position corresponding to the modified nucleotide in the antisense strand.
[0134] In some embodiments, the chemical modification shown in formula (I') above or a tautomer modification thereof is [ka] and those in which the adenine in those structures is replaced with guanine, cytosine, uracil, or thymine, but are not limited to these.
[0135] In some embodiments, at least one nucleotide among positions 2 to 8 (e.g., positions 2, 3, 4, 5, 6, 7, 8) of the 5' region of the antisense strand comprises a 2'-methoxy modification.
[0136] In some embodiments, any one of nucleotides 5, 6, and 7 of the 5' region of the antisense strand comprises a 2'-methoxy modification.
[0137] In some embodiments, the modified nucleotide is located at any one of positions 2-8 of the 5' region of the antisense strand.
[0138] In some embodiments, the modified nucleotide is located at any one of positions 5, 6, or 7 of the 5' region of the antisense strand.
[0139] In some embodiments, when the chemical modification shown in Formula (I') or a tautomer modification thereof is at the 5th position of the 5' region, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole, and in some embodiments, B is a base at a position corresponding to the 5th position of the 5' region of the antisense strand.
[0140] In some embodiments, when the chemical modification shown in formula (I') or a tautomer modification thereof is at position 6 of the 5' region, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole, and in some embodiments, B is a base at a position corresponding to position 6 of the 5' region of the antisense strand.
[0141] In some embodiments, when the chemical modification shown in formula (I') or a tautomer modification thereof is at position 7 of the 5' region, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole, and 3-nitropyrrole, and in some embodiments, B is a base at a position corresponding to position 7 of the 5' region of the antisense strand.
[0142] In some embodiments, at least one additional nucleotide of the siRNA sense strand and / or antisense strand is a modified nucleotide selected from 2'-methoxy modified nucleotide, 2'-substituted alkoxy modified nucleotide, 2'-alkyl modified nucleotide, 2'-substituted alkyl modified nucleotide, 2'-amino modified nucleotide, 2'-substituted amino modified nucleotide, 2'-fluoro modified nucleotide, 2'-deoxy nucleotide, 2'-deoxy-2'-fluoro modified nucleotide, 3'-deoxy-thymine nucleotide, isonucleotide, LNA, ENA, cET, UNA, GNA. In some embodiments, the modified nucleotide is independently selected from 2'-methoxy modified nucleotide, 2'-fluoro modified nucleotide and 2'-deoxy modified nucleotide.
[0143] In some embodiments, three consecutive nucleotides in the sense strand of the siRNA are 2'-fluoro modified nucleotides.
[0144] In some embodiments, in the sense strand of the siRNA, three consecutive nucleotides located at positions 7 to 9 of the 5' end are 2'-fluoro modified nucleotides.
[0145] In some embodiments, in the sense strand of the siRNA, three consecutive nucleotides located at positions 7 to 9 at the 5' end are 2'-fluoro modified nucleotides, and all remaining positions in the sense strand are non-2'-fluoro modified nucleotides.
[0146] In some embodiments, in the 5' to 3' direction, the nucleotides at positions 2, 4, 6, 9, 12, 14, 16, and 18 of the antisense strand are each independently a 2'-fluoro modified nucleotide.
[0147] In some embodiments, in the 5' to 3' direction, the nucleotides at positions 2, 4, 6, 10, 12, 14, 16, and 18 of the antisense strand are each independently a 2'-fluoro modified nucleotide.
[0148] In some embodiments, the sense strand comprises the nucleotide sequence (5'-3') shown in the formula below:
[0149] N a N a N a N a XN a N b N b N b N a N a N a N a N a N a N a N a N a N a Wherein, each X is independently N a Or N b and N a is a nucleotide modified with a 2'-methoxy group, and N b is a 2'-fluoro modified nucleotide.
[0150] In some embodiments, the sense strand is 5'-N a N a N a N a N a N a N b N b N b N a N a N a N a N a N a N a N a N a N a -3', or 5'-N a N a N a N a N b N a N b N b N b N a N a N a N a N a N a N a N a N a N a -3', Of these, N a is a nucleotide modified with a 2'-methoxy group, and N b is a 2'-fluoro modified nucleotide.
[0151] In some embodiments, the sense strand is 5'-N a N a N a N a N a N a N b N b N b N a N a N a N a N a N a N a N a N a N a -3', or 5'-N a N a N a N a N b N a N b N b N b N a N a N a N a N a N a N a N a Na N a -3', Of these, N a is a nucleotide modified with a 2'-methoxy group, and N b is a 2'-fluoro modified nucleotide.
[0152] In some embodiments, the antisense strand is 5'-N a 'N b 'N a 'N b 'N a 'N b 'W'N a 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N a 'N a '-3', or 5'-N a 'N b 'N a 'N b 'N a 'N b 'W'N a 'N b 'N a 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N a 'N a '-3', Of these, N a ' is a nucleotide modified with a 2'-methoxy group, and N bW' represents a nucleotide modified with a 2'-fluoro group, or a nucleotide containing the chemical modification shown in formula (I) or a tautomeric modification thereof.
[0153] In some specific embodiments, W' represents a nucleotide containing a chemical modification as shown in formula (I) or a tautomeric modification thereof: In some specific embodiments, formula (I) is [ka] wherein B is selected from guanine, adenine, cytosine, or uracil. In some specific embodiments, B is selected from the base at the position corresponding to position 7 of the 5' region of the antisense strand.
[0154] In some specific embodiments, formula (I) is [ka] wherein M is O or S, and wherein B is selected from guanine, adenine, cytosine, or uracil. In some specific embodiments, B is selected from the base at the position corresponding to position 7 of the 5' region of the antisense strand.
[0155] In some specific embodiments, M is S. In some specific embodiments, M is O.
[0156] In some specific embodiments, W' represents a nucleotide modified with a 2'-methoxy group.
[0157] In some embodiments, at least one phosphate group in sense strand and / or antisense strand is a phosphate group having a modification group.By virtue of the modification group, the siRNA has improved stability in biological samples or environments.In some embodiments, the phosphate group having the modification group is a thiophosphate group.
[0158] In some embodiments, the thiophosphate group is Between the first and second nucleotides of the 5'-terminal end of the sense strand, Between the second and third nucleotides of the 5'-terminal end of the sense strand, the first nucleotide terminus of the 3'-terminal end of the sense strand; Between the first and second nucleotides of the 3'-terminal end of the sense strand, Between the second and third nucleotides of the 3'-terminal end of the sense strand, Between the first and second nucleotides at the 5'-end of the antisense strand, Between the second and third nucleotides of the 5'-terminal end of the antisense strand, the first nucleotide end of the 3' end of the antisense strand; Between the first and second nucleotides at the 3'-terminal end of the antisense strand, and Between the second and third nucleotides of the 3'-terminal end of the antisense strand, It is present in at least one position selected from the positions:
[0159] In some embodiments, the sense strand and / or the antisense strand comprises a plurality of thiophosphate groups, the thiophosphate groups being: Between the first and second nucleotides at the 5'-terminal end of the sense strand, and Between the second and third nucleotides at the 5'-terminal end of the sense strand, and Between the first and second nucleotides at the 5'-terminal end of the antisense strand, and Between the second and third nucleotides at the 5'-end of the antisense strand, and Between the first and second nucleotides at the 3'-terminal end of the antisense strand, and Between the second and third nucleotides of the 3'-terminal end of the antisense strand, It is present in at least one position selected from the positions:
[0160] In some embodiments, the sense strand is 5'-NmsNmsNmNmNfNmNfNfNfNmNmNmNmNmNmNmNmNmNm-3', or 5'-NmsNmsNmNmNmNmNfNfNfNmNmNmNmNmNmNmNmNmNm-3', or 5'-NmsNmsNmNmNfNmNfNfNmNmNmNmNmNmNmNmNmNms-3', or 5'-NmsNmsNmNmNmNmNfNfNfNmNmNmNmNmNmNmNmNmNms-3', or 5'-NmsNmsNmNmNfNmNfNfNmNmNmNmNmNmNmNmNmNmsNm-3', or 5'-NmsNmsNmNmNmNmNfNfNfNmNmNmNmNmNmNmNmNmsNm-3', or 5'-NmsNmsNmNmNfNmNfNfNmNmNmNmNmNmNmNmNmsNms-3', or 5'-NmsNmsNmNmNmNmNmNfNfNfNmNmNmNmNmNmNmNmNmsNms-3', The nucleotide sequence represented by the formula: Wherein, Nm represents any nucleotide modified with a 2'-methoxy group, for example, C, G, U, A modified with a 2'-methoxy group, Nf represents any nucleotide modified with a 2'-fluoro group, for example, C, G, U, A modified with a 2'-fluoro group, The lower case letter s indicates that the two nucleotides adjacent to the letter s are linked by a thiophosphate group, and when the lower case letter s is at the first position of the 3' end, it indicates that one phosphate group adjacent to the letter s upstream is a thiophosphate group.
[0161] In some embodiments, the antisense strand is 5'-Nm'sNf'sNm'Nf'Nm'Nf'W'Nm'Nm'Nf'Nm'Nf'Nm'Nf'Nm'Nf'Nm'Nf'Nm'sNm'sNm'-3' or 5'-Nm'sNf'sNm'Nf'Nm'Nf'W'Nm'Nf'Nm'Nm'Nf'Nm'Nf'Nm'Nf'Nm'Nf'Nm'sNm'sNm'-3', The nucleotide sequence represented by the formula: Wherein, Nm' represents any nucleotide modified with a 2'-methoxy group, for example, C, G, U, A modified with a 2'-methoxy group, Nf' represents any nucleotide modified with a 2'-fluoro group, for example, C, G, U, A modified with a 2'-fluoro group, The lower case letter s indicates that the two nucleotides adjacent to the letter s are linked by a thiophosphate group, and when the lower case letter s is at the first position of the 3' end, it indicates that one phosphate group adjacent to the letter s upstream is a thiophosphate group.
[0162] W' represents a nucleotide modified with a 2'-methoxy group or a nucleotide containing the chemical modification shown in formula (I) or a tautomeric modification thereof.
[0163] In some embodiments, formula (I) is [ka] wherein B is selected from guanine, adenine, cytosine, or uracil. In some embodiments, B is the base at the position corresponding to position 7 of the 5' region of the antisense strand.
[0164] In some embodiments, formula (I) is [ka] wherein M is O or S, and wherein B is selected from guanine, adenine, cytosine, or uracil. In some specific embodiments, B is the base at the position corresponding to position 7 of the 5' region of the antisense strand.
[0165] In some specific embodiments, M is S. In some specific embodiments, M is O.
[0166] In some embodiments, the sense strand comprises a sequence that differs from any one of SEQ ID NOs: 1 to 6 by 3 or less nucleotides and comprises at least 15 consecutive nucleotides.
[0167] In some embodiments, the sense strand comprises a sequence that differs from any one of SEQ ID NOs:1 to 6 by no more than three nucleotides and comprises at least 19 contiguous nucleotides, and in some embodiments, the nucleotide sequence differs by no more than one nucleotide.
[0168] In some embodiments, the antisense strand comprises a sequence that differs from any one of SEQ ID NOs: 13 to 18 by no more than 3 nucleotides and comprises at least 21 consecutive nucleotides, and in some embodiments, the nucleotide sequence differs by no more than 1 nucleotide, wherein W' represents a nucleotide modified with a 2'-methoxy group, or a nucleotide comprising a chemical modification shown in formula (I) or a tautomer modification thereof.
[0169] In some embodiments, the sense strand nucleotide is selected from any one of SEQ ID NO:1 to SEQ ID NO:6.
[0170] In some embodiments, the antisense strand nucleotide is selected from any one of SEQ ID NO: 13 to SEQ ID NO: 18, wherein W' represents a nucleotide modified with a 2'-methoxy group, or a nucleotide containing a chemical modification shown in formula (I) or a tautomer modification thereof.
[0171] In some embodiments, formula (I) is [ka] wherein B is selected from guanine, adenine, cytosine, or uracil. In some embodiments, B is the base at the position corresponding to position 7 of the 5' region of the antisense strand.
[0172] In some embodiments, formula (I) is [ka] wherein M is O or S; and wherein B is selected from guanine, adenine, cytosine, or uracil; in some specific embodiments, B is the base at the position corresponding to position 7 of the 5' region of the antisense strand.
[0173] In some specific embodiments, M is S. In some specific embodiments, M is O.
[0174] In some specific embodiments, the sense strand comprises any one of SEQ ID NO:135 to SEQ ID NO:162.
[0175] In some specific embodiments, the antisense strand comprises any one of SEQ ID NOs:189 to 216, 243 to 259, and 273 to 289.
[0176] In some specific embodiments, the sense strand is selected from any one of SEQ ID NO: 135 to SEQ ID NO: 162; In some specific embodiments, the antisense strand is selected from any one of SEQ ID NOs: 189 to 216, 243 to 259, and 273 to 289.
[0177] In some specific embodiments, the siRNA comprises a sense strand and an antisense strand selected from any one of Table 26.
[0178] In some specific embodiments, the siRNA described herein comprises: An siRNA according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 140 and the antisense strand is selected from SEQ ID NO: 194; or An siRNA according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 143 and the antisense strand is selected from SEQ ID NO: 197; or An siRNA according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 144 and the antisense strand is selected from SEQ ID NO: 199; or An siRNA according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 146 and the antisense strand is selected from SEQ ID NO: 200; or An siRNA according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 147 and the antisense strand is selected from SEQ ID NO: 201; or An siRNA according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 148 and the antisense strand is selected from SEQ ID NO: 202; or An siRNA according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 149 and the antisense strand is selected from SEQ ID NO: 203; or An siRNA according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 150 and the antisense strand is selected from SEQ ID NO: 204; or An siRNA according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 151 and the antisense strand is selected from SEQ ID NO: 205; or An siRNA according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 152 and the antisense strand is selected from SEQ ID NO: 206; or An siRNA according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 153 and the antisense strand is selected from SEQ ID NO: 207; or An siRNA according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 154 and the antisense strand is selected from SEQ ID NO: 208; or An siRNA according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 155 and the antisense strand is selected from SEQ ID NO: 209; or The siRNA is selected from any one of the siRNAs described in the present disclosure, wherein the sense strand is selected from SEQ ID NO: 156 and the antisense strand is selected from SEQ ID NO: 210.
[0179] The present disclosure further provides a siRNA complex or a dsRNA comprising any one of the above siRNAs and a targeting ligand linked to the above siRNA.
[0180] In some embodiments, the targeting ligand comprises a targeting moiety.
[0181] In some embodiments, the siRNA is covalently or non-covalently linked to said targeting ligand.
[0182] In some embodiments, the targeting ligand is targeted to the liver. In some embodiments, the targeting ligand binds to the asialoglycoprotein receptor (ASGPR). In some embodiments, the targeting ligand comprises a galactose cluster or a galactose derivative cluster. The galactose derivative is selected from N-acetyl-galactosamine, N-trifluoroacetylgalactosamine, N-propionylgalactosamine, Nn-butyrylgalactosamine, or N-isobutyrylgalactosamine.
[0183] In some embodiments, the targeting ligand is linked to the 3' end of the sense strand of the siRNA.
[0184] In some embodiments, lipophilic groups such as cholesterol can be introduced at the end of the siRNA sense strand to facilitate siRNA entry into cells. Lipophilic groups are covalently linked to siRNA (e.g., cholesterol, lipoprotein, vitamin E, etc., introduced at the end) to act on intracellular mRNA through cell membranes composed of lipid bilayers. At the same time, siRNA can also be modified non-covalently (e.g., by binding to phospholipid molecules, polypeptides, cationic polymers, etc., by hydrophobic or ionic bonds) to improve stability and biological activity.
[0185] In some embodiments, the targeting ligand is linked to the siRNA end via a phosphate group, a thiophosphate group or a phosphoric acid group. In some embodiments, the targeting ligand is linked indirectly to the siRNA end via a phosphate group, a thiophosphate group or a phosphoric acid group. In some embodiments, the targeting ligand is linked directly to the siRNA end via a phosphate group, a thiophosphate group or a phosphoric acid group. In some embodiments, the targeting ligand is linked directly to the siRNA end via a phosphate group or a thiophosphate group. In some embodiments, the targeting ligand is linked directly to the siRNA sense strand 3' end via a phosphate group or a thiophosphate group.
[0186] In some embodiments, the targeting ligand cooperates in directing the delivery of the therapeutic reagent linked thereto to a desired target location. In some cases, the targeting moiety can bind to a cell or cell receptor and trigger endocytosis to facilitate entry of the therapeutic reagent into the cell. The targeting moiety can include a compound that has affinity for a cell receptor or a cell surface molecule. A variety of targeting ligands, including targeting moieties, can be linked to therapeutic reagents and other compounds to target the reagent to a cell and a specific cell receptor.
[0187] In some embodiments, the types of targeting moieties include carbohydrates, cholesterol and cholesteryl groups or steroids. Targeting moieties capable of binding to cell receptors include sugars such as galactose, galactose derivatives (e.g., N-acetyl-galactosamine, N-trifluoroacetylgalactosamine, N-propionylgalactosamine, Nn-butyrylgalactosamine, N-isobutyrylgalactosamine), mannose and mannose derivatives.
[0188] It is known that targeting moieties coupled to the asialoglycoprotein receptor (ASGPR) can be used to specifically target oligomeric compounds (e.g., siRNA or its complexes or dsRNA) to the liver. The asialoglycoprotein receptor is abundantly expressed in liver cells. Targeting moieties of cellular receptors targeting ASCPR include galactose and galactose derivatives. Specifically, galactose derivative clusters containing clusters of two, three, four or more N-acetyl-galactosamines (GalNAc or NAG) can promote the uptake of certain compounds in liver cells. The GalNAc clusters coupled to the oligomeric compounds are for targeting therapeutic agents to the liver, and the N-acetyl-galactosamine sugars can bind to the asialoglycoprotein receptor on the surface of liver cells. Binding to the asialoglycoprotein receptor is believed to promote the entry of therapeutic agents into the cell interior by initiating receptor-mediated endocytosis.
[0189] In some embodiments, the targeting ligand may comprise two, three, four or more targeting moieties. In some embodiments, the targeting ligands disclosed herein may comprise one, two, three, four or more targeting moieties linked to a branching group via L2.
[0190] In some embodiments, the targeting ligand is in the form of a galactose cluster.
[0191] In some embodiments, each targeting moiety is independently a galactosamine derivative, which is N-acetyl-galactosamine. Other sugars that can be used as targeting moieties and have affinity for the asialoglycoprotein receptor may be selected from galactose, galactosamine, N-formyl-galactosamine, N-propionyl-galactosamine, N-butyryl-galactosamine, and N-isobutyryl-galactosamine, and the like.
[0192] In some embodiments, the targeting ligands of the present disclosure comprise N-acetylgalactosamine as a targeting moiety.
[0193] [ka] .
[0194] In some embodiments, the targeting ligand comprises three terminal galactosamines or galactosamine derivatives (e.g., N-acetyl-galactosamines), each of which has affinity for a sialoglycoprotein receptor. In some embodiments, the targeting ligand comprises three terminal N-acetyl-galactosamines (GalNAc or NAG) as targeting moieties.
[0195] In some embodiments, the targeting ligand comprises four terminal galactosamines or galactosamine derivatives (e.g., N-acetyl-galactosamines), each of which has affinity for the asialoglycoprotein receptor. In some embodiments, the targeting ligand comprises four terminal N-acetyl-galactosamines (GalNAc or NAG) as targeting moieties.
[0196] When referring to three terminal N-acetyl-galactosamines, terms commonly used in the art include tri-antennary, tri-valent and trimer.
[0197] When referring to four terminal N-acetyl-galactosamines, terms commonly used in the art include tri-antennary, tri-valent and tetramer.
[0198] In some embodiments, the targeting ligand is selected from a compound represented by formula (II) or a pharma- ceutically acceptable salt thereof: [ka] Of these, L1 is C1-C 30 C1-C which is an alkyl chain or is interrupted by one or more oxygen, sulfur, nitrogen atoms or C=O. 30 Contains an alkyl chain, R 11 and R 12 are independently chemical bonds, NR 16 , C=O or -OC(=O)-, Q3 is, [ka] and [ka] is a single bond or a double bond, and [ka] is a single bond, R 13 is independently CR 17 R 18 , N.R. 16 , O or S; [ka] If is a double bond, R 13 is independently CR 19 or N, R 14 is independently CR 19 or N, Ring A is a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, which may or may not be present, and when Ring A is present, R 15 is independently CR 19 or N, and when ring A is absent, R 15 is independently CR 17 R 18 , N.R. 16 or O, R 16 and R 19 are independently hydrogen, deuterium, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, SR', S(=O)R', S(=O)2R', S(=O)2NR'(R"), NR'(R"), C(=O)R', C(=O)OR' or C(=O)NR'(R"), wherein the alkyl group, alkoxy group, cycloalkyl group, heterocycloalkyl group, aryl group or heteroaryl group is optionally selected from the group consisting of halogen, hydroxyl group, oxo, nitro group, cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-7 substituted with one or more groups selected from a cycloalkyl group, a 3- to 12-membered heterocycloalkyl group, a 6- to 12-membered aryl group, a 5- to 12-membered heteroaryl group, SR', S(=O)R', S(=O)2R', S(=O)2NR'(R"), NR'(R"), C(=O)R', C(=O)OR' and C(=O)NR'(R"); R 17 and R 18 are independently hydrogen, deuterium, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, SR', S(=O)R', S(=O)2R', S(=O)2NR'(R"), NR'(R"), C(=O)R', C(=O)OR' or C(=O)NR'(R"), wherein the alkyl group, alkoxy group, cycloalkyl group, heterocycloalkyl group, aryl group or heteroaryl group is optionally selected from the group consisting of halogen, hydroxyl group, oxo, nitro group, cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-7substituted with one or more groups selected from a cycloalkyl group, a 3- to 12-membered heterocycloalkyl group, a 6- to 12-membered aryl group, a 5- to 12-membered heteroaryl group, SR', S(=O)R', S(=O)2R', S(=O)2NR'(R"), NR'(R"), C(=O)R', C(=O)OR' and C(=O)NR'(R"); R' and R'' are independently hydrogen, deuterium, a hydroxyl group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, wherein the alkyl group, the alkoxy group, the cycloalkyl group, the heterocycloalkyl group, the aryl group, or the heteroaryl group is optionally substituted with one or more substituents selected from a halogen, a hydroxyl group, an oxo group, a nitro group, and a cyano group; m1, n1, p1 and q1 are independently 0, 1, 2, 3 or 4; B1 is, [ka] and R b1 , R b2 , R b3 , R b4 , R b5 , R b6 and R b7 are independently -C(=O)-, -NHC(=O)-, -C(=O)O-, -C(=O)-(CH2) z8 -O- or -NHC(=O)-(CH2) z9 -O-, z1, z2, z3, z4, z5, z6, z7, z8, and z9 are independently an integer of 0 to 10; L2 is C1-C 30 C1-C which is an alkyl chain or is interrupted by one or more oxygen, sulfur, nitrogen atoms or C=O. 30 Contains an alkyl chain, r1 is an integer from 1 to 10.
[0199] In some embodiments, L is C 30C1-C which is an alkyl chain or is interrupted by one or more oxygen, sulfur, nitrogen atoms or C=O. 30 Contains an alkyl chain, R 11 and R 12 are independently chemical bonds, NR 16 or C=O, Q3 is, [ka] and R 13 CR 17 R 18 , N.R. 16 , O or S; R 14 CR 19 and R 15 is independently CR 17 R 18 , N.R. 16 or O, R 16 ~R 19 are independently hydrogen, deuterium, or an alkyl group; m1, p1 and q1 are independently 0, 1, 2, 3 or 4; B1 is, [ka] and R b5 , R b6 and R b7 are independently -C(=O)-, -NHC(=O)-, -C(=O)O-, -C(=O)-(CH2) z8 -O- or -NHC(=O)-(CH2) z9 -O-, z5, z6, z7, z8, and z9 are independently an integer of 0 to 10; L2 is C1-C 30 C1-C which is an alkyl chain or is interrupted by one or more oxygen, sulfur, nitrogen atoms or C=O. 30 Contains an alkyl chain, r1 is an integer from 1 to 10.
[0200] In some embodiments, L1 is -(CH2) j11 -C(=O)-(CH2) j12 - and R 11 and R 12 are independently chemical bonds, NR 16 or C=O, R 16 is hydrogen or C 1-6 is an alkyl group, Q3 is, [ka] and R 13 CR 17 R 18 or O, R 14 CR 19 and R 15 is independently CR 17 R 18 or O, R 17 ~R 19 are independently hydrogen or an alkyl group; m1, p1 and q1 are independently 0 or 1; B1 is, [ka] and R b5 , R b6 and R b7 are independently -C(=O)-(CH2) z8 -O- or -NHC(=O)-(CH2) z9 -O-, z8 and z9 are independently an integer from 0 to 10; L2 is -(CH2) j15 -(OCH2CH2) 1-4 -(CH2) j16 -or [ka] and j15 and j16 are independently an integer of 0 to 4; r1 is 3, 4, 5 or 6.
[0201] In some embodiments, L1 is L3 or L3-R 110 -R 111 -L3, wherein L3 is independently C1-C 12 Alkyl chain, -(CH2) j11 -C(=O)-(CH2) j12 -or-(CH2) j13 -(CH2CH2O) 1-4 -(CH2) j14 - and R 110 and R 111 are independently chemical bonds, -NR 112 -, -C(=O)- or -OC(=O)-, R 112 is hydrogen or C1-C 12 An alkyl group, and j11, j12, j13, and j14 are independently an integer of 0 to 10. In some embodiments, j11, j12, j13, and j14 are independently an integer of 0 to 2 or 4 to 10. In some embodiments, j11, j12, j13, and j14 are independently 0, 1, 2, 6, 7, 8, 9, or 10.
[0202] In some embodiments, L1 is -(CH2) j11 -C(=O)-(CH2) j12 -, and the definitions of j11 and j12 are as described in any one of the above forms.
[0203] In some embodiments, L1 is [ka] The definition of j12 is as described in any one of the above embodiments, wherein the a1 end is linked to B1 and the b1 end is R11 Concatenate to.
[0204] In some embodiments, L1 is [ka] wherein the a1 end is linked to B1 and the b1 end is linked to R 11 Concatenate to.
[0205] In some embodiments, R 11 may be a chemical bond, and R 12 may be C=O.
[0206] In some embodiments, R 11 may be a chemical bond, and R 12 is NR 16 R may be 16 is as defined in any one of the above forms.
[0207] In some embodiments, R 11 may be a chemical bond, and R 12 may be -OC(=O)-.
[0208] In some embodiments, R 11 is NR 16 and R 12 may be C=O, R 16 is as defined in any one of the above forms.
[0209] In some embodiments, R is NR 16 and R 12 may be -OC(=O)-, R 16 is as defined in any one of the above forms.
[0210] In some embodiments, R 12 is NR 16 and R11 may be C=O, R 16 is as defined in any one of the above forms.
[0211] In some embodiments, R 12 is NR 16 and R 11 may be -OC(=O)-, R 16 is as defined in any one of the above forms.
[0212] In some embodiments, R 11 may be NH, and R 12 may be C=O.
[0213] In some embodiments, R 12 may be NH, and R 11 may be C=O.
[0214] In some embodiments, R 16 is hydrogen or C 1-6 It may be an alkyl group.
[0215] In some embodiments, R 16 may be hydrogen, a methyl group, an ethyl group, a propyl group, or an isopropyl group.
[0216] In some embodiments, R 16 may be hydrogen.
[0217] In some embodiments, R 17 and R 18 may be hydrogen.
[0218] In some embodiments, R 19 may be hydrogen.
[0219] In some embodiments, when ring A is present, ring A is C 6-12 It may be an aryl group.
[0220] In some embodiments, ring A can be a phenyl group.
[0221] In some embodiments, m1 may be 0 or 1.
[0222] In some embodiments, m1 may be 3.
[0223] In some embodiments, n1 may be 0 or 1.
[0224] In some embodiments, p1 and q1 are independently 0 or 1.
[0225] In some embodiments, p1=1 and q1=1.
[0226] In some embodiments, p1=1 and q1=0.
[0227] In some embodiments, p1=0 and q1=1.
[0228] In some embodiments, p1=0 and q1=0.
[0229] In some embodiments, z1, z2, z3, z4, z5, z6, z7, z8, and z9 may independently be an integer from 0 to 4. In some embodiments, z1, z2, z3, z4, z5, z6, z7, z8, and z9 may independently be 0, 1, or 2.
[0230] In some embodiments, B1 is [ka] R may be b1 , R b2 , R b3 and R b4are independently -C(=O)- or -NHC(=O)-, the N atom is linked to L1, and the definitions of z1, z2, z3 and z4 are as described in any one of the above forms.
[0231] In some embodiments, B1 is [ka] R may be b1 , R b2 , R b3 and R b4 are independently -C(=O)- or -NHC(=O)-, the N atom is connected to L1, and R b1 , R b3 and R b4 are the same, and the definitions of z1, z2, z3, and z4 are as described in any one of the above forms.
[0232] In some embodiments, B1 is [ka] may be also possible.
[0233] In some embodiments, B1 is [ka] may be also possible.
[0234] In some embodiments, B1 is [ka] R may be b5 , R b6 and R b7 are independently -C(=O)-(CH2) z8 -O- or -NHC(=O)-(CH2) z9-O-, the N atom is linked to L1, and the definitions of z5, z6, z7, z8 and z9 are as described in any one of the above forms.
[0235] In some embodiments, B1 is [ka] R may be b5 , R b6 and R b7 are independently -C(=O)-(CH2) z8 -O- or -NHC(=O)-(CH2) z9 -O-, the N atom is linked to L1, and R b5 , R b6 and R b7 are the same, and the definitions of z5, z6, z7, z8, and z9 are as described in any one of the above forms.
[0236] In some embodiments, B1 is [ka] may be also possible.
[0237] In some embodiments, L2 is L4 or L4-R 13 -R 14 -L4, wherein L4 is independently C1-C 12 Alkyl chain or -(CH2) j15 -(OCH2CH2) 1-4 -(CH2) j16 - and R 13 and R 14 are independently chemical bonds, -NR 115 -, -C(=O)- or -OC(=O)-, R 115 are independently hydrogen or C1-C 12An alkyl group, and j15 and j16 are independently an integer from 0 to 10. In some embodiments, j15 and j16 are independently an integer from 0 to 6. In some embodiments, j15 and j16 are independently 0, 1, 2, 3, or 4.
[0238] In some embodiments, L2 is -(CH2) j15 -(OCH2CH2) 1-4 -(CH2) j16 -, and the definitions of j15 and j16 are as described in any one of the above forms.
[0239] In some embodiments, L2 is [ka] In some embodiments, L2 may be [ka] wherein one side is linked to the O atom and the other side is linked to B1.
[0240] In some embodiments, L2 is C1-C 12 It may also be an alkyl chain.
[0241] In some embodiments, L2 is [ka] may be also possible.
[0242] In some embodiments, L2 is [ka] In some embodiments, L2 may be [ka] In some embodiments, L2 may be [ka] In some embodiments, L2 may be [ka] wherein the a3 end is linked to an O atom and the b3 end is linked to B1.
[0243] In some embodiments, L2 is [ka] wherein the a3 end is linked to an O atom and the b3 end is linked to B1.
[0244] In some embodiments, r1 may be 3, 4, 5, or 6. In some embodiments, r1 may be 3.
[0245] In some embodiments, Q3 is [ka] In some embodiments, Q3 may be: [ka] Among them, R 13 , R 14 , R 15 and n1 is as defined in any one of the above forms.
[0246] In some embodiments, [ka] In addition, R 13 , R 14 , R 15 , p1 and q1 are as defined in any one of the above forms.
[0247] In some embodiments, [ka] In addition, R 13 , R 14 , R 15 The definitions of p1 and q1 are as described in any one of the above forms.
[0248] In some embodiments, [ka] In some embodiments, [ka] In some embodiments, [ka] The definitions of p1 and q1 are as described in any one of the above forms.
[0249] In some embodiments, [ka] may be also possible.
[0250] In some embodiments, [ka] may be also possible.
[0251] In some embodiments, [ka] The definitions of p1 and q1 are as described in any one of the above forms.
[0252] In some embodiments, [ka] In addition, R 13 , R 14 , n1, p1 and q1 are as defined in any one of the above forms.
[0253] In some embodiments, [ka] In addition, R 13 , R 14 , n1, p1 and q1 are as defined in any one of the above forms.
[0254] In some embodiments, [ka] In some embodiments, [ka] The definitions of n1, p1, and q1 are as described in any one of the above forms.
[0255] In some embodiments, [ka] wherein the definitions of n1, p1, and q1 are as described in any one of the above forms.
[0256] In some embodiments, the targeting ligand is: [ka] [ka] [ka] [ka] or a pharma- ceutically acceptable salt thereof.
[0257] In some embodiments, the targeting ligand is: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a pharma- ceutically acceptable salt thereof.
[0258] In some embodiments, the targeting ligand is: [ka] or a pharma- ceutically acceptable salt thereof.
[0259] In some embodiments, N-trifluoroacetylgalactosamine, N-propionylgalactosamine, Nn-butyrylgalactosamine, or N-isobutyrylgalactosamine can be substituted for the N-acetylgalactosamine moiety in the targeting ligand.
[0260] In some embodiments, the siRNA is covalently or non-covalently linked to the targeting ligand.
[0261] In some embodiments, the 3' and / or 5' end of the sense strand is conjugated to the targeting ligand.
[0262] In some embodiments, the 3' end of the sense strand is conjugated to the targeting ligand.
[0263] In some embodiments, the targeting ligand is linked to the siRNA terminus via a phosphate group (a phosphodiester group) or a thiophosphate group (a phosphodiester group).
[0264] In some embodiments, the targeting ligand is linked to the 3' end of the sense strand of the siRNA via a phosphate group (a phosphodiester group) or a thiophosphate group (a phosphodiester group).
[0265] In some specific embodiments, the sense strand comprises any one of SEQ ID NOs: 163 to 188; In some specific embodiments, the antisense strand comprises any one of SEQ ID NOs:217 to 242, SEQ ID NOs:260 to 272, and SEQ ID NOs:290 to 302.
[0266] In some specific embodiments, the sense strand is selected from any one of SEQ ID NO: 163 to SEQ ID NO: 188; In some specific embodiments, the antisense strand is selected from any one of SEQ ID NOs: 217 to 242, 260 to 272, and 290 to 302.
[0267] In some specific embodiments, the dsRNA or siRNA complex comprises a sense strand and an antisense strand selected from any one of Table 26.
[0268] In some specific embodiments, the dsRNA or siRNA complex comprises: A dsRNA or siRNA complex or compound according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 163 and the antisense strand is selected from SEQ ID NO: 217; or A dsRNA or siRNA complex or compound according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 172 and the antisense strand is selected from SEQ ID NO: 226; or A dsRNA or siRNA complex or compound according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 173 and the antisense strand is selected from SEQ ID NO: 227; or A dsRNA or siRNA complex or compound according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 174 and the antisense strand is selected from SEQ ID NO: 228; or A dsRNA or siRNA complex or compound according to the present disclosure, wherein the sense strand is selected from SEQ ID NO: 175 and the antisense strand is selected from SEQ ID NO: 229; or The sense strand is selected from SEQ ID NO: 176 and the antisense strand is selected from SEQ ID NO: 230.
[0269] In some embodiments, the dsRNA or siRNA complex has the following structure, or a pharma- ceutically acceptable salt thereof: [ka] , among which: Af = adenine 2'-F ribonucleoside, Cf = cytosine 2'-F ribonucleoside, Uf = uracil 2'-F ribonucleoside; Gf = guanine 2'-F ribonucleoside, Am = adenine 2'-OMe ribonucleoside, Cm = cytosine 2'-OMe ribonucleoside, Gm = guanine 2'-OMe ribonucleoside, Um = uracil 2'-OMe ribonucleoside.
[0270] [ka] represents a thiophosphodiester group, [ka] represents a phosphodiester group, NAG0052 is [ka] represents (-)hmpNA(C) [ka] Represents.
[0271] In some embodiments, the pharma- ceutically acceptable salt may be a conventional salt in the art, including but not limited to sodium salt, potassium salt, ammonium salt, amine salt, etc. In some embodiments, the dsRNA or siRNA complex is selected from TRD008096, TJR100053, TJR100296.
[0272] In some embodiments, the dsRNA or siRNA complex is TRD008096, the structure of which is as follows:
[0273] [ka] In some embodiments, the dsRNA or siRNA complex is TJR100053, the structure of which is as follows:
[0274] [ka] In some embodiments, the dsRNA is TJR100296, the structure of which is as follows:
[0275] [ka] Among them, Af = adenine 2'-F ribonucleoside, Cf = cytosine 2'-F ribonucleoside, Uf = uracil 2'-F ribonucleoside; Gf = guanine 2'-F ribonucleoside, Am = adenine 2'-OMe ribonucleoside, Cm = cytosine 2'-OMe ribonucleoside, Gm = guanine 2'-OMe ribonucleoside, Um = uracil 2'-OMe ribonucleoside.
[0276] [ka] represents a thiophosphodiester group, [ka] represents a phosphodiester group, NAG0052 is [ka] represents (-)hmpNA(C) [ka] Represents.
[0277] Another aspect of the present disclosure is a method for producing a method for manufacturing a semiconductor device comprising the steps of: Group 1) consisting of the sense strand shown in SEQ ID NO: 1 and the antisense strand shown in SEQ ID NO: 7; Group 2) the sense strand shown in SEQ ID NO: 2 and the antisense strand shown in SEQ ID NO: 8; Group 3) consisting of the sense strand shown in SEQ ID NO: 3 and the antisense strand shown in SEQ ID NO: 9; Group 4) the sense strand shown in SEQ ID NO: 4 and the antisense strand shown in SEQ ID NO: 10; Group 5) the sense strand shown in SEQ ID NO:5 and the antisense strand shown in SEQ ID NO:11; Group 6) consisting of the sense strand shown in SEQ ID NO:6 and the antisense strand shown in SEQ ID NO:12; The present invention provides a compound selected from any one of the following:
[0278] The present disclosure provides a compound comprising a sense strand selected from any one of SEQ ID NO:135 to SEQ ID NO:162, and an antisense strand selected from any one of SEQ ID NO:189 to SEQ ID NO:216, SEQ ID NO:243 to SEQ ID NO:259, and SEQ ID NO:273 to SEQ ID NO:289.
[0279] The present disclosure provides a compound comprising a sense strand selected from any one of SEQ ID NO:163 to SEQ ID NO:188, and an antisense strand selected from any one of SEQ ID NO:217 to SEQ ID NO:242, SEQ ID NO:260 to SEQ ID NO:272, and SEQ ID NO:290 to SEQ ID NO:302.
[0280] The present disclosure provides compounds comprising a sense strand and an antisense strand selected from any one of Table 26.
[0281] Another aspect of the present disclosure provides a composition comprising an siRNA, siRNA complex or dsRNA, or a compound described in this disclosure, and one or more pharma- ceutically acceptable excipients, such as a vehicle, carrier, diluent, and / or delivery polymer.
[0282] A variety of drug delivery systems are known and can be applied to the siRNA or siRNA complexes or dsRNA of the present disclosure, such as packaging in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the siRNA or siRNA complexes or dsRNA, receptor-mediated cellular endocytosis, construction of the nucleic acid as part of a reverse transcribing virus or other vector.
[0283] Another aspect of the disclosure provides the use of the above-described siRNA, siRNA complex or dsRNA or composition in the preparation of a medicament for treating a disease in a subject, which in some embodiments is selected from a liver-derived disease.
[0284] Another aspect of the disclosure provides a method of treating a disease in a subject, comprising administering to the subject an siRNA, siRNA complex or dsRNA or composition as described above.
[0285] Another aspect of the present disclosure provides a method of inhibiting mRNA expression in a subject, comprising administering to the subject an siRNA, siRNA complex or dsRNA or composition as described above.
[0286] Another aspect of the present disclosure provides a method for delivering an expression-inhibitory oligomeric compound to the liver in vivo, comprising administering to a subject the above-described siRNA, siRNA complex or dsRNA or composition.
[0287] The siRNA, siRNA complex or dsRNA or compositions and methods disclosed herein can reduce the level of a target mRNA in a cell, cell population, cell population, tissue, or subject, comprising administering to a subject a therapeutically effective amount of a siRNA, siRNA complex or dsRNA or composition described herein, wherein the siRNA is linked to a targeting ligand, thereby inhibiting expression of the target mRNA in the subject.
[0288] In some embodiments, the subject has previously been identified as having a pathogenic upregulation of a target gene in a target cell or tissue.
[0289] A subject as described in this disclosure refers to a subject suffering from (or suspected of suffering from, or susceptible to) a disease or condition that would benefit from the reduction or inhibition of target mRNA expression.
[0290] Delivery may be local (e.g., direct injection, implantation, or topical administration), systemic, or by subcutaneous, intravenous, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal and intrathecal), intramuscular, transdermal, airway (aerosol), nasal, oral, rectal, or topical (including buccal and sublingual) administration.
[0291] In alternative embodiments, the pharmaceutical compositions provided by the present disclosure may be administered by injection, for example, intravenous, intramuscular, intradermal, subcutaneous, intraduodenal, or intraperitoneal injection.
[0292] In an alternative embodiment, after the targeting ligand is linked to the siRNA to form a complex, the complex may be packaged into a reagent kit.
[0293] The present disclosure further provides a pharmaceutical composition comprising a siRNA or siRNA complex or a dsRNA according to the present disclosure.
[0294] In some embodiments, the pharmaceutical composition may further include a pharma- ceutically acceptable additive and / or adjuvant, which may be one or more of a variety of agents or compounds commonly used in the art. For example, the pharma- ceutically acceptable additive may include at least one of a pH buffer, a protectant, and an osmolality adjuster.
[0295] In some embodiments, when the siRNA, siRNA complex or dsRNA or pharmaceutical composition is contacted with a cell expressing the target gene, the siRNA, siRNA complex or dsRNA or pharmaceutical composition will inhibit expression of the target gene by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% as measured (e.g., by psiCHECK activity screening, luciferase reporter gene detection, PCR or branched DNA (bDNA) based methods, or protein based methods such as immunofluorescence analysis, Western Blot, or flow cytometry).
[0296] In some embodiments, when the siRNA, siRNA complex or dsRNA or pharmaceutical composition is contacted with a cell expressing the target gene, the percentage over-expression of the target gene mRNA by the siRNA, siRNA complex or dsRNA or pharmaceutical composition is 99% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, or 10% or less as measured (e.g., by psiCHECK activity screening and luciferase reporter gene detection, PCR or branched DNA (bDNA) based methods, or protein based methods such as immunofluorescence analysis, Western Blot, or flow cytometry).
[0297] In some embodiments, when the siRNA, siRNA complex or dsRNA, or pharmaceutical composition is contacted with a cell expressing the target gene, the siRNA, siRNA complex or dsRNA, or pharmaceutical composition retains on-target activity and reduces off-target activity by at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70% or at least 75% as measured (e.g., by psiCHECK activity screening and luciferase reporter gene detection, PCR or branched DNA (bDNA) based methods, or protein based methods such as immunofluorescence analysis, Western Blot, or flow cytometry).
[0298] In some embodiments, the siRNA, siRNA complex or dsRNA, or pharmaceutical composition, when contacted with a cell expressing the target gene, reduces on-target activity by at most 20%, at most 19%, at most 15%, at most 10%, at most 5%, or 1% or more, and reduces off-target activity by at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%, as measured (e.g., by psiCHECK activity screening and luciferase reporter gene detection, PCR or branched DNA (bDNA) based methods, or protein based methods such as immunofluorescence analysis, Western Blot, or flow cytometry).
[0299] In some embodiments, when the siRNA, siRNA complex, or dsRNA or pharmaceutical composition contacts a cell that expresses the target gene, the target gene is expressed as measured (e.g., by psiCHECK activity screening and luciferase reporter gene detection methods, PCR or branched DNA (bDNA)-based methods, or protein-based methods, e.g., immunofluorescence analysis, Western blotting, or immunoassay. Blot, or flow cytometry), the siRNA, siRNA complex or dsRNA or pharmaceutical composition has increased on-target activity by at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% or at least 80%, and reduced off-target activity by at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70% or at least 75%.
[0300] The present disclosure further provides a cell comprising an siRNA or an siRNA complex or a dsRNA according to the present disclosure.
[0301] The present disclosure further provides a reagent kit comprising an siRNA or siRNA complex or dsRNA according to the present disclosure.
[0302] The present disclosure further provides a method for silencing a target gene or a target gene mRNA in a cell, the method comprising the step of introducing into the cell an siRNA, siRNA complex or dsRNA and / or a pharmaceutical composition according to the present disclosure.
[0303] The present disclosure further provides a method for silencing a target gene or a target gene mRNA in a cell, either in vivo or in vitro, comprising introducing into said cell an siRNA, siRNA complex or dsRNA and / or a pharmaceutical composition according to the present disclosure.
[0304] The present disclosure further provides a method for inhibiting expression of a target gene or mRNA of a target gene, comprising administering to a subject in need thereof an effective amount or dose of an siRNA, siRNA complex or dsRNA and / or pharmaceutical composition according to the present disclosure.
[0305] In some embodiments, administration is by routes including intramuscular, intrabronchial, intrathoracic, intraperitoneal, intraarterial, intralymphatic, intravenous, subcutaneous, cerebrospinal, or combinations thereof.
[0306] In some embodiments, an effective amount or effective dose of the siRNA, siRNA complex or dsRNA and / or pharmaceutical composition is from about 0.001 mg / kg body weight to about 200 mg / kg body weight, from about 0.01 mg / kg body weight to about 100 mg / kg body weight, or from about 0.5 mg / kg body weight to about 50 mg / kg body weight.
[0307] In some embodiments, the target gene is the AGT gene.
[0308] The present disclosure further provides a pharmaceutical composition comprising a siRNA or siRNA complex or a dsRNA according to the present disclosure.
[0309] In some embodiments, the pharmaceutical composition may further include a pharma- ceutically acceptable additive and / or adjuvant, which may be one or more of a variety of agents or compounds commonly used in the art. For example, the pharma- ceutically acceptable additive may include at least one of a pH buffer, a protectant, and an osmolality adjuster.
[0310] In some embodiments, when the siRNA complex or dsRNA or pharmaceutical composition is contacted with a cell expressing AGT, the siRNA complex or dsRNA or pharmaceutical composition will inhibit expression of AGT by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% as measured (e.g., by PCR or branched DNA (bDNA) based methods, or protein based methods such as immunofluorescence analysis, Western Blot, or flow cytometry).
[0311] In some embodiments, when the siRNA complex or dsRNA or pharmaceutical composition is contacted with a cell expressing AGT, the percentage of excess expression of AGT mRNA by the siRNA complex or dsRNA or pharmaceutical composition is 99% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, or 10% or less, as measured (e.g., by PCR or branched DNA (bDNA) based methods, or protein based methods such as immunofluorescence analysis, Western Blot, or flow cytometry).
[0312] The present disclosure provides a method for inhibiting AGT gene expression, comprising administering to a subject an effective amount or dose of a siRNA, siRNA complex or dsRNA or pharmaceutical composition according to the present disclosure.
[0313] The present disclosure provides a method for treating and / or preventing a disease associated with expression of the AGT gene in a subject, the method comprising administering to the subject an effective amount or dose of an siRNA, siRNA complex or dsRNA or pharmaceutical composition described in the present disclosure.
[0314] The present disclosure provides a method for treating and / or preventing a disease associated with the RAAS pathway in a subject, the method comprising administering to the subject an effective amount or dose of an siRNA, siRNA complex or dsRNA or pharmaceutical composition described in the present disclosure.
[0315] The present disclosure provides a method for treating and / or preventing a disease, comprising administering to a subject an effective amount or dose of an siRNA or siRNA complex or dsRNA or pharmaceutical composition described in the present disclosure. In some embodiments, the disease is selected from hypertension or heart disease. In some embodiments, the disease is selected from borderline hypertension, essential hypertension, secondary hypertension, isolated systolic or diastolic hypertension, pregnancy-related hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt hypertension, hypertension associated with low plasma renin activity or plasma renin concentration, ocular hypertension, glaucoma, pulmonary arterial hypertension, portal venous hypertension, systemic venous hypertension, systolic hypertension, unstable hypertension, hypertensive heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis, vascular disorder, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiomyopathy, glomerulosclerosis, aortic stenosis, aortic aneurysm, ventricular fibrosis, heart failure, myocardial infarction, angina pectoris, heart valve disease, stroke, kidney disease, renal failure, systemic sclerosis, intrauterine growth retardation (IUGR), fetal growth restriction, obesity, hepatic steatosis / fatty liver, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), impaired glucose tolerance, type 2 diabetes (non-insulin dependent diabetes mellitus) and metabolic syndrome.
[0316] The present disclosure provides a method for delivering siRNA to the liver that inhibits expression and / or replication of the AGT gene in the body, the method comprising administering to a subject an siRNA or siRNA complex or dsRNA or pharmaceutical composition described in the present disclosure.
[0317] The present disclosure further provides a method of preparing an siRNA or an siRNA complex or a dsRNA, the method comprising synthesizing an siRNA, an siRNA complex or a dsRNA or a pharmaceutical composition described in this disclosure.
[0318] The present disclosure further provides an siRNA or siRNA complex or dsRNA, characterized in that a T base replaces one or more, e.g., 1, 2, 3, 5, 6, 7, 8, 9, 10, U bases of any one of the siRNAs or siRNA complexes or dsRNAs according to the present disclosure. Pharmaceutically acceptable salts of the compounds described in the present disclosure are selected from inorganic salts or organic salts, and the compounds described in the present disclosure can react with acidic or basic substances to produce the corresponding salts.
[0319] In another embodiment, if no configuration is specified, the compounds of the present disclosure may have a particular geometric or stereoisomeric form. The present disclosure includes all cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic and other mixtures thereof, such as mixtures enriched in enantiomers or diastereomers, and all such compounds are intended to be within the scope of the present disclosure. Substituents such as alkyl groups may have other asymmetric carbon atoms. All such isomers and mixtures thereof are within the scope of the present disclosure.
[0320] Also, unless a configuration is specified, the compounds and intermediates of the present disclosure may exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible by a low energy barrier. For example, proton tautomers (also called protolytic tautomers) include interconversions by protolysis, such as keto-enol and imine-enamine, lactam-lactim isomerization, etc. An example of lactam-lactim equilibrium is between A and B as shown below.
[0321] [ka] All of the compounds in this disclosure can be depicted in Form A or Form B. All tautomeric forms are within the scope of this disclosure. The naming of a compound does not exclude any tautomeric forms.
[0322] The compounds of the present disclosure may be asymmetric, e.g., have one or more stereoisomers.Unless otherwise specified, all stereoisomers include, e.g., enantiomers and diastereomers.The compounds of the present disclosure that contain asymmetric carbon atoms can be isolated in optically pure form or racemic form.Optical pure forms can be resolved from racemic mixtures or synthesized by using chiral raw materials or chiral reagents.
[0323] Optically active (R)- and (S)-isomers and D- and L-isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. To obtain one enantiomer of a compound of the present disclosure, it can be prepared by asymmetric synthesis or derivatization with chiral auxiliaries, in which the resulting diastereomeric mixture is isolated and the required enantiomer is purified by cleavage of the auxiliaries. Alternatively, if the molecule contains a basic (e.g., amino) or acidic (e.g., carboxy) functional group, the diastereomeric salt can be formed with an appropriate optically active acid or base, and the diastereomeric separation can be carried out by conventional methods well known in the art, followed by recovery to obtain the enantiomer in pure form. Note that the separation of enantiomers and diastereomers is generally accomplished by chromatography, which employs a chiral stationary phase and is optionally combined with a chemical derivatization method (e.g., forming a carbamate from an amine).
[0324] The present disclosure further includes certain isotopically labeled compounds of the present disclosure that are the same as those described herein, but in which one or more atoms are replaced with an atom having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Illustrative examples of isotopes that can be attached to the compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, e.g., 2H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 123 I, 125 I and 36 Cl, etc.
[0325] Unless otherwise stated, when a position is specifically designated as deuterium (D), it should be understood that the position is deuterium (i.e., at least 10% deuterium incorporated) with an abundance at least 1000 times higher than the natural abundance of deuterium (which is 0.015%). In the example compounds, having an abundance higher than the natural abundance of deuterium may be at least 1000 times more abundant deuterium, at least 2000 times more abundant deuterium, at least 3000 times more abundant deuterium, at least 4000 times more abundant deuterium, at least 5000 times more abundant deuterium, at least 6000 times more abundant deuterium, or more abundant deuterium. The present disclosure further includes various deuterated forms of the compounds of formula I and formula II. Each available hydrogen atom connected to a carbon atom may be independently replaced with a deuterium atom. Those skilled in the art can synthesize deuterated forms of the compounds of formula I and formula II with reference to the relevant literature. Deuterated forms of the compounds of Formula I and Formula II may be prepared using commercially available deuterated starting materials or may be synthesized by conventional techniques with deuterated reagents including, but not limited to, deuterated borane, tritiated borane in tetrahydrofuran, lithium aluminum deuteride, deuterated iodoethane, deuterated iodomethane, and the like.
[0326] Unless otherwise specified, in the chemical structures of the compounds described in this disclosure, [ka] indicates that the configuration is not specified, i.e., if chiral isomers are present in the chemical structure, [ka] The bond [ka] or [ka] or [ka] and [ka] For convenience, all of the above structural formulas are depicted in certain isomeric forms, but the present disclosure includes all isomers, such as tautomers, rotamers, geometric isomers, diastereomers, racemates, and enantiomers. In the chemical structures of the compounds described in the present disclosure, [ka] The bond is unspecified in configuration, i.e. [ka] The bond configuration may be the E configuration or the Z configuration, or may include both E and Z configurations simultaneously. Explanation of terms
[0327] In order that the present disclosure may be more readily understood, certain technical and scientific terms are specifically defined below. Unless otherwise expressly defined herein, all other technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art.
[0328] Unless otherwise specified, in the context of the present disclosure, the terms "angiotensinogen" and "AGT" are used interchangeably herein. AGT is also called SERPINA8 and ANHU. AGT includes, but is not limited to, human AGT, cynomolgus monkey AGT, mouse AGT, and rat AGT, and their amino acid and complete coding sequences and mRNA sequences can be easily obtained using previously disclosed databases such as GenBank, UniProt, OMIM, and Macaca genome planktonic site.
[0329] The term "AGT" also refers to naturally occurring DNA sequence variations of the AGT gene, such as single nucleotide polymorphisms (SNPs) in the AGT gene. Exemplary SNPs can be found in the dbSNP database.
[0330] The term "target sequence" refers to a continuous portion of the nucleotide sequence of an mRNA molecule formed during AGT gene transcription, including the RNA processing product mRNA as the primary transcription product. The targeted portion of the target sequence must be of sufficient length to serve as a substrate for iRNA-directed cleavage. In one embodiment, the target sequence is within the protein coding region of AGT.
[0331] As used herein, in the context of RNA-mediated gene silencing, the sense strand (also referred to as SS, SS strand or significant strand) of an siRNA refers to a strand that contains the same or essentially the same sequence as a target mRNA sequence, and the antisense strand (also referred to as AS or AS strand) of an siRNA refers to a strand having a sequence complementary to the target mRNA sequence.
[0332] In the context of describing the siRNA sense strand described herein, the term "a sequence that differs by no more than 3 nucleotides from the nucleotide sequence of any one of SEQ ID NO:1 to SEQ ID NO:6, and that comprises at least 15 consecutive nucleotides" is intended to indicate that the siRNA sense strand described herein comprises at least 15 consecutive nucleotides of the sense strand of any one of SEQ ID NO:1 to SEQ ID NO:6, or a sequence that differs by no more than 3 nucleotides from the at least 15 consecutive nucleotides of the sense strand of any one of SEQ ID NO:1 to SEQ ID NO:6 (optionally, a sequence that differs by no more than 2 nucleotides, optionally, a sequence that differs by no more than 1 nucleotide). Optionally, the siRNA sense strand described herein comprises at least 16 consecutive nucleotides of the sense strand of any one of SEQ ID NO:1 to SEQ ID NO:6, or a sequence that differs by no more than 3 nucleotides from the at least 16 consecutive nucleotides of the sense strand of any one of SEQ ID NO:1 to SEQ ID NO:6 (optionally, a sequence that differs by no more than 2 nucleotides, optionally, a sequence that differs by no more than 1 nucleotide).
[0333] In the context of describing the siRNA antisense strand described herein, the term "a sequence that differs by no more than 3 nucleotides from the antisense strand of any one of SEQ ID NO:7 to SEQ ID NO:12, and that contains at least 15 consecutive nucleotides" is intended to indicate that the siRNA antisense strand described herein contains at least 15 consecutive nucleotides of the antisense strand of any one of SEQ ID NO:7 to SEQ ID NO:12, or a sequence that differs by no more than 3 nucleotides from at least 15 consecutive nucleotides of the antisense strand of any one of SEQ ID NO:7 to SEQ ID NO:12 (optionally, a sequence that differs by no more than 2 nucleotides, optionally, a sequence that differs by no more than 1 nucleotide).
[0334] In the present disclosure, the "5' region" or "5' end" of the sense strand or antisense strand is used interchangeably. For example, nucleotides 2 to 8 of the 5' region of the antisense strand may be substituted with nucleotides 2 to 8 of the 5' end of the antisense strand. Similarly, the "3' region", "3' end" and "3' end" of the sense strand or antisense strand are also used interchangeably.
[0335] Unless otherwise specified, in the context of this disclosure, capital letters C, G, U, A, and T indicate the composition of nucleotide bases, lower case letter d indicates that one nucleotide adjacent to the downstream side of the letter d is a deoxyribonucleotide, lower case letter m indicates that one nucleotide adjacent to the upstream side of the letter m is a methoxy-modified nucleotide, lower case letter f indicates that one nucleotide adjacent to the upstream side of the letter f is a fluoro-modified nucleotide, and lower case letter s indicates that the two nucleotides adjacent to the letter s are linked together by a thiophosphate group.
[0336] As used in this disclosure, the term "2'-fluoro modified nucleotide" refers to a nucleotide formed by replacing the hydroxy group at the 2' position of the ribosyl group of a nucleotide with a fluoro, and "non-2'-fluoro modified nucleotide" refers to a nucleotide or nucleotide analog formed by replacing the hydroxy group at the 2' position of the ribosyl group of a nucleotide with a non-fluoro group.
[0337] As used in this disclosure, the term "2'-methoxy modified nucleotide" refers to a nucleotide formed by replacing the 2'-hydroxy group of a ribosyl group with a methoxy group.
[0338] As used herein, the terms "complementary" and "reverse complementary" may be used interchangeably and have the meaning known to those of skill in the art that in a double-stranded nucleic acid molecule, bases in one strand pair with bases in another strand in a complementary manner. In DNA, the purine base adenine (A) always pairs with the pyrimidine base thymine (t) (or uracil (U) in RNA), and the purine base guanine (C) always pairs with the pyrimidine base cytosine (G). Each base pair contains one purine and one pyrimidine. If adenine in one strand always pairs with thymine (or uracil) in the other strand, and guanine always pairs with cytosine, then the two strands are said to be complementary to each other, and the sequence of the strand can be deduced from the sequence of its complementary strand. Accordingly, a "mismatch" as used in the art means that in a double-stranded nucleic acid, bases at corresponding positions are not present paired in a complementary form.
[0339] As used herein, the term "inhibition" can be used interchangeably with "reduction," "silencing," "downregulation," "suppression," and other similar terms, and includes any level of inhibition. Inhibition can be assessed by a reduction in the absolute or relative level of one or more of these variables as compared to a control level. The control level can be any type of control level used in the art, such as a pre-administration baseline level or a level determined from an untreated or control (e.g., buffer control or inactive agent control only) treated subject, cell, or sample. For example, the degree of inhibition of target gene expression by siRNA can be indicated by the amount of excess mRNA expression, for example, the amount of excess mRNA expression is 99% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, or 10% or less. The inhibition rate of target gene expression can be detected using the Dual-Glo (registered trademark) Luciferase Assay System. The firefly chemiluminescence value (Fir) and Renilla chemiluminescence value (Ren) are read, and the relative value Ratio = Ren / Fir is calculated. In the present disclosure, the proportion of mRNA excess expression (or excess activity %) = Ratio (siRNA-treated group) / Ratio (siRNA-free control group), and the inhibition rate (%) = 100% - mRNA excess expression (%).
[0340] Unless otherwise specified, any of the "compounds," "ligands," "nucleic acid-ligand complexes," "nucleic acids," "complexes," "chemical modifications," "ligands," "dsRNAs," and "RNAi" disclosed herein can independently exist in the form of a salt, mixed salt, or non-salt (e.g., free acid or free base). If present in the form of a salt or mixed salt, it may be a pharma- ceutically acceptable salt.
[0341] The term "pharmaceutically acceptable salts" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0342] "Pharmaceutically acceptable acid addition salt" refers to a salt formed with an inorganic or organic acid that is capable of retaining the bioavailability of the free base without other adverse effects. Inorganic acid salts include, but are not limited to, hydrochloride, hydrobromide, sulfate, nitrate, phosphate, etc., and organic acid salts include, but are not limited to, formate, acetate, 2,2-dichloroacetate, trifluoroacetate, propionate, caproate, octanoate, decanoate, undecylenate, glycolate, gluconate, lactate, sebacate, adipate, glutarate, malonate, oxalate, maleate, succinate, fumarate, tartrate, citrate, palmitate, stearate, oleate, cinnamate, laurate, malate, glutamate, pyroglutamate, aspartate, benzoate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, alginate, ascorbate, salicylate, 4-aminosalicylate, naphthalenedisulfonate, etc. These salts can be prepared by methods known in the art.
[0343] "Pharmaceutically acceptable base addition salt" refers to a salt formed with an inorganic or organic base that can retain the bioavailability of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, etc. Preferred inorganic salts are ammonium salts, sodium salts, potassium salts, calcium salts and magnesium salts, with sodium salts being preferred. Salts derived from organic bases include, but are not limited to, the following salts: primary amines, secondary amines, and tertiary amines, substituted amines including natural substituted amines, cyclic amines, and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, glycine betaine, ethylenediamine, glucosamine, methylglucosamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamide resins, and the like. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine. These salts can be prepared by methods known in the art.
[0344] An "effective amount" or "effective dose" is the amount of a drug, compound, or pharmaceutical composition required to obtain any one or more beneficial or desired therapeutic results. For prophylactic use, beneficial or desired results include biochemical, histological, and / or behavioral manifestations of a disease state, its complications, and intermediate pathological phenotypes manifested during the progression of a disease state, including eliminating or reducing the risk, reducing the severity, or delaying the onset of a disease state. For therapeutic applications, beneficial or desired results include clinical results such as reducing the incidence of or improving one or more symptoms of a disease state associated with various target genes, target mRNAs, or target proteins of the present disclosure, reducing the dosage of other drugs required to treat the disease state, improving the therapeutic efficacy of another drug, and / or delaying the progression of a disease state associated with a target gene, target mRNA, or target protein of the present disclosure in a patient.
[0345] As used herein, the terms "patient," "subject," or "individual" are used interchangeably and include a human or a non-human animal, such as a mammal, for example, a human or a monkey.
[0346] The siRNA provided by the present disclosure can be obtained by conventional preparation methods in the field (such as solid-phase synthesis and liquid-phase synthesis methods). Among them, solid-phase synthesis has already been commercialized as a customization service. The modified nucleotide group can be introduced into the siRNA described in the present disclosure by the nucleoside monomer having the corresponding modification, and the method of preparing the nucleoside monomer having the corresponding modification and the method of introducing the modified nucleotide group into the siRNA are also well known to those skilled in the art.
[0347] A "chemical modification" or "modification" includes any alteration of a nucleotide by chemical means, such as the addition or removal of a chemical moiety, or the substitution of one chemical moiety for another.
[0348] The term "base" includes any known DNA and RNA base and base analogs, such as purines and pyrimidines, as well as the naturally occurring compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs.
[0349] The terms "flat-ended" or "blunt-ended" are used interchangeably and refer to the absence of unpaired nucleotides or nucleotide analogs at a given end of the siRNA, i.e., the absence of nucleotide overhangs. In most cases, an siRNA with two blunt ends is double-stranded over its entire length.
[0350] The term "about" or "approximately" means that a numerical value is within an acceptable error range of a specific value as measured by a person skilled in the art, and is determined by how the numerical portion is measured (i.e., the limitations of the measurement system). For example, "about" may mean within 1 or more than 1 standard deviation. Alternatively, "about" or "essentially including" may mean varying within a range of up to 20%, for example, between 1% and 15%, between 1% and 10%, between 1% and 5%, between 0.5% and 5%, between 0.5% and 1%. In the present disclosure, the term "about" preceding a number or a numerical range also includes, in each case, the number of embodiments specified. Unless otherwise stated, when a specific value appears in the present application and claims, the meaning of "about" or "essentially including" should be assumed to be within an acceptable error range of the specific value.
[0351] Unless otherwise specified, "optionally," "optionally," "optionally," or "alternatively" means that the subsequently described event or circumstance may or may not occur, and the description includes cases where the event or circumstance occurs and cases where it does not occur. For example, "optionally, R1 and R2 are directly linked to form a ring" means that R1 and R2 may be directly linked to form a ring, but are not required to be present, and the description includes cases where R1 and R2 are directly linked to form a ring and cases where R1 and R2 do not form a ring.
[0352] In this disclosure, the term "comprising" may be substituted with "consisting of."
[0353] The term "alkyl group" refers to a saturated aliphatic hydrocarbon group that is a straight or branched chain group containing from 1 to 20 carbon atoms. In some embodiments, it is selected from alkyl groups containing from 1 to 12 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 6-methylhexyl, 7-methylhexyl, 8-methylhexyl, 9-methylhexyl, 10-methylhexyl, 11-methylhexyl, 12-methylhexyl, 13-methylhexyl, 14-methylhexyl, 15-methylhexyl, 16-methylhexyl, 17-methylhexyl, 18-methylhexyl, 19-methylhexyl, 20-methylhexyl, 21-methylhexyl, 22-methylhexyl, 23-methylhexyl, 24-methylhexyl, 25-methylhexyl, 26-methylhexyl, 27-methylhexyl, 28-methylhexyl, 29-methylhexyl, 30-methylhexyl, 31-methylhexyl, 32-methylhexyl, 33-methylhexyl, 34-methylhexyl, 35-methylhexyl, 36-methylhexyl, 37-methylhexyl, 38-methylhexyl, 39-methylhexyl, 40-methylhexyl, 41-methylhexyl, 42-methylhexyl, 43-methylhex Examples of such groups include 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof.In some embodiments, alkyl groups are selected from those containing 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. An alkyl group can be substituted or unsubstituted, and when substituted, the substituents can be substituted at any available attachment point, which in some embodiments are independently selected from one or more groups selected from alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylthio groups, alkylamino groups, halogens, mercapto groups, hydroxy groups, nitro groups, cyano groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, cycloalkoxy groups, heterocycloalkoxy groups, cycloalkylthio groups, heterocycloalkylthio groups, oxo groups, carboxy groups, or carboxylic acid ester groups.
[0354] The term "alkoxy group" refers to -O-(alkyl group) and -O-(unsubstituted cycloalkyl group), where alkyl group is defined above. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, and cyclohexyloxy. An alkoxy group may be optionally substituted or unsubstituted, and when substituted, the substituents, in some embodiments, are independently selected from halogen, deuterium, hydroxy, oxo, nitro, cyano, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 2-6 Alkenyloxy group, C 2-6 Alkynyloxy group, C3-6 Cycloalkoxy groups, 3- to 6-membered heterocycloalkoxy groups, C 3-8 a cycloalkenyloxy group, a 5- to 6-membered aryl group, or a heteroaryl group; 1-6 Alkyl group, C 1-6 Alkoxy group, C 2-6 Alkenyloxy group, C 2-6 Alkynyloxy group, C 3-6 Cycloalkoxy groups, 3- to 6-membered heterocycloalkoxy groups, C 3-8 The cycloalkenyloxy group, the 5- to 6-membered aryl group, or the heteroaryl group is optionally substituted with one or more groups selected from halogen, deuterium, a hydroxy group, an oxo group, a nitro group, and a cyano group. Similarly, the definitions of "alkynyloxy group", "alkenyloxy group", "cycloalkoxy group", "heterocycloalkoxy group", and "cycloalkenyloxy group" are the same as those of the above "alkoxy group".
[0355] The term "alkenyl group" refers to a straight or branched chain non-aromatic hydrocarbon group containing at least one carbon-carbon double bond and having 2 to 10 carbon atoms. There may be up to 5 carbon-carbon double bonds in such a group. For example, a "C2-C6" alkenyl group is defined as an alkenyl group having 2 to 6 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl, propenyl, butenyl, and cyclohexenyl groups. The straight, branched, or cyclic portions of the alkenyl group may contain double bonds and are optionally 1-, 2-, 3-, 4-, or 5-substituted at any position allowed by normal valences.
[0356] The term "cycloalkenyl group" refers to a monocyclic hydrocarbon group having the specified number of carbon atoms and at least one carbon-carbon double bond.
[0357] The term "alkynyl group" refers to a straight or branched chain hydrocarbon group containing 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Up to five carbon-carbon triple bonds may be present. Thus, a "C2-C6 alkynyl group" refers to an alkenyl group having 2 to 6 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl, 2-propynyl, and 2-butynyl groups. The straight and branched chain portions of the alkynyl group may contain triple bonds as permitted by normal valences, and are optionally 1-, 2-, 3-, 4-, or 5-substituted at any position permitted by normal valences.
[0358] The term "ketone" refers to any alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl group linked by a carbonyl bridge, as described herein. Examples of ketone groups include, but are not limited to, alkanoyl groups (e.g., acetyl, propionyl, butyryl, valeryl, hexanoyl), alkenoyl groups (e.g., acryloyl), alkynoyl groups (e.g., acetylenic acyl, propynoyl, butynoyl, pentanoyl, hexanoyl), aroyl groups (e.g., benzoyl), and heteroaroyl groups (e.g., pyrroloyl, imidazoyl, quinolyl, pyridyloyl).
[0359] The term "alkoxycarbonyl group" refers to any alkoxy group (i.e., -C(O)O-alkyl group) linked by a carbonyl bridge, as defined above. Examples of alkoxycarbonyl groups include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, n-propoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl or n-pentyloxycarbonyl groups.
[0360] The term "aryloxycarbonyl group" refers to any aryl group, as defined above, linked by an oxycarbonyl bridge (i.e., -C(O)O-aryl group). Examples of aryloxycarbonyl groups include, but are not limited to, phenoxycarbonyl and naphthyloxycarbonyl groups.
[0361] The term "heteroaryloxycarbonyl group" refers to any heteroaryl group linked by an oxycarbonyl bridge (i.e., -C(O)O-heteroaryl group), as defined above. Examples of heteroaryloxycarbonyl groups include, but are not limited to, 2-pyridyloxycarbonyl group, 2-oxazolyloxycarbonyl group, 4-thiazolyloxycarbonyl group or pyrimidinyloxycarbonyl group.
[0362] The term "cycloalkyl group" or "carbocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms. In some embodiments, it is selected from those containing 3 to 7 carbon atoms. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, and the like. Polycyclic cycloalkyl groups include spiro, fused, and bridged ring cycloalkyl groups. Cycloalkyl groups may be substituted or unsubstituted. If substituted, the substituents may be substituted at any available attachment point. In some embodiments, the cycloalkyl groups may be independently selected from halogen, deuterium, hydroxy, oxo, nitro, cyano, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 2-6 Alkenyloxy group, C 2-6 Alkynyloxy group, C 3-6 Cycloalkoxy groups, 3- to 6-membered heterocycloalkoxy groups, C 3-8 a cycloalkenyloxy group, a 5- to 6-membered aryl group, or a heteroaryl group; 1-6 Alkyl group, C1-6 Alkoxy group, C 2-6 Alkenyloxy group, C 2-6 Alkynyloxy group, C 3-6 Cycloalkoxy groups, 3- to 6-membered heterocycloalkoxy groups, C 3-8 The cycloalkenyloxy group, the 5- to 6-membered aryl group, or the heteroaryl group is optionally substituted with one or more groups selected from halogen, deuterium, a hydroxy group, an oxo group, a nitro group, and a cyano group.
[0363] The cycloalkyl ring may be fused to an aryl or heteroaryl group, in which the ring connected to the parent structure is a cycloalkyl group, non-limiting examples of which include indanyl, tetrahydronaphthyl, benzocycloheptanyl, etc. Cycloalkyl groups may be optionally substituted or unsubstituted, and when substituted, the substituents, in some embodiments, are independently halogen, deuterium, hydroxy, oxo, nitro, cyano, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 2-6 Alkenyloxy group, C 2-6 Alkynyloxy group, C 3-6 Cycloalkoxy groups, 3- to 6-membered heterocycloalkoxy groups, C 3-8 a cycloalkenyloxy group, a 5- to 6-membered aryl group, or a heteroaryl group; 1-6 Alkyl group, C 1-6 Alkoxy group, C 2-6 Alkenyloxy group, C 2-6 Alkynyloxy group, C 3-6 Cycloalkoxy groups, 3- to 6-membered heterocycloalkoxy groups, C 3-8 The cycloalkenyloxy group, the 5- to 6-membered aryl group, or the heteroaryl group is optionally substituted with one or more groups selected from halogen, deuterium, a hydroxy group, an oxo group, a nitro group, and a cyano group.
[0364] The term "heterocycloalkyl group" or "heterocycle" or "heterocyclyl group" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is selected from the group consisting of nitrogen, oxygen, or S(O). m (wherein m is an integer from 0 to 2), but does not include the ring moieties -OO-, -OS-, or -SS-, with the remaining ring atoms being carbon. In some embodiments, it is selected from those containing 3 to 12 ring atoms, of which 1 to 4 are heteroatoms. In some embodiments, it is selected from those containing 3 to 7 ring atoms. Non-limiting examples of monocyclic heterocycloalkyl groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and the like. Polycyclic heterocycloalkyl groups include spiro, fused, and bridged ring heterocycloalkyl groups. Non-limiting examples of "heterocycloalkyl groups" include: [ka] etc.
[0365] The term "hydroxy" refers to an -OH group.
[0366] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0367] The term "haloalkyl group" refers to an alkyl group substituted with a halogen, wherein alkyl group is defined above.
[0368] The term "cyano" refers to -CN.
[0369] The term "nitro group" refers to --NO.sub.2.
[0370] The term "oxo" refers to a =O group, e.g., a carbon atom attached by a double bond to an oxygen atom, thereby forming a ketone or aldehyde group.
[0371] The term "amino group" refers to -NH2.
[0372] The term "carboxy" refers to -C(O)OH.
[0373] The term "aldehyde group" refers to --CHO.
[0374] In the chemical structures of the present disclosure: [ka] may be attached to any one or more groups in accordance with the scope of the invention described herein, and the asterisk "*" represents a chiral center.
[0375] In this disclosure, unless otherwise specified, a "phosphate group" is a phosphodiester group.
[0376] As used herein, a thiophosphate group refers to a phosphodiester group modified by replacing one of the non-bridging oxygen atoms with a sulfur atom; [ka] (M is an S atom).
[0377] In the context of this disclosure: [ka] Based on [ka] can be substituted with any group capable of linking to an adjacent nucleotide.
[0378] The term "linked," when referring to a connection between two molecules, refers to whether the two molecules are joined by a covalent bond or whether the two molecules are joined by a non-covalent bond (e.g., a hydrogen bond or an ionic bond), and includes a direct link and an indirect link.
[0379] The term "directly linked" refers to a connection between a first compound or group and a second compound or group without any intervening atoms or groups.
[0380] The term "indirectly linked" refers to a connection between a first compound or group and a second compound or group through an intermediate group, compound or molecule (eg, a linking group).
[0381] The term "substituted" refers to the replacement of any one or more hydrogen atoms on a particular atom (usually carbon, oxygen, and nitrogen atoms) with any group as defined herein, provided that the valence does not exceed the normal valence of the particular atom and results in the formation of a stable compound. Non-limiting examples of substituents include C1-C6 alkyl groups, C2-C6 alkenyl groups, C2-C6 alkynyl groups, cyano groups, hydroxy groups, oxo groups, carboxy groups, cycloalkyl groups, cycloalkenyl groups, heterocyclyl groups, heteroaryl groups, aryl groups, ketones, alkoxycarbonyl groups, aryloxycarbonyl groups, heteroaryloxycarbonyl groups, or halogens (F, Cl, Br, I, etc.). When the substituent is ketone or oxo (i.e., =O), two (2) hydrogens on the atom are replaced.
[0382] "Substituted with one or more" means that the group may be substituted with a single or multiple substituents. Substitution with multiple substituents may be multiple of the same substituent or may be a combination of one or multiple different substituents.
[0383] Several abbreviations in this disclosure are defined as follows: DCE: dichloroethane; Sc(OTf)3: scandium trifluoromethanesulfonate, TFH: tetrahydrofuran; Pd / C: palladium-carbon; TFA: trifluoroacetic acid; DMF: dimethylformamide, DIPEA: N-ethyldiisopropylamine, HoBt: 1-hydroxybenzotriazole; EDCI: 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride; DMTrCl: 4,4'-dimethoxytrityl chloride; DIEA: N,N-diisopropylethylamine, HATU: 2-(7-azabenzotriazazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate; LiOH: lithium hydroxide; DMAP: 4-dimethylaminopyridine; HBTU: benzotriazazole-N,N,N',N'-tetramethyluronium hexafluorophosphate; DMTrCl: 1-[chloro(4-methoxyphenyl)benzyl]-4-methoxybenzene; CF3SO3H: trifluoromethanesulfonic acid, BnBr: benzyl bromide; DEPBT: 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4-one; Bz: benzoyl protecting group, MMTr: methoxyphenylbenzhydryl; DMTr: dimethoxytrityl protecting group. [Brief description of the drawings]
[0384] [Figure 1] This shows the mRNA expression level in TTR on day 7 after administration of TRD002218 and TRD007205. [Diagram 2] This shows the mRNA expression level in TTR on day 28 after administration of TRD002218 and TRD007205. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0385] The present disclosure will be further described below in conjunction with examples, but these examples are not intended to limit the scope of the present disclosure. Experimental methods for which specific conditions are not specified in the examples of the present disclosure generally follow normal conditions or conditions recommended by the manufacturers of raw materials or products. For reagents for which a specific source is not specified, the reagents can be obtained from any molecular biology reagent supplier with the quality / purity for molecular biology applications. Part 1. Off-target modification
[0386] Example 1. Preparation of Chemical Modifications 1.1 Synthesis of Compound 1-1a and Compound 1-1b [ka] Compound 1 (500mg, 3.42mmol) and triethylamine (Et3N, 692mg, 6.84mmol, 0.95mL) were dissolved in dichloromethane (DCM, 10mL), and a solution of 4-toluenesulfonyl chloride (tsCl, 717mg, 3.76mmol) in dichloromethane (10mL) was added dropwise in an ice bath. After the addition was completed, the reaction was allowed to proceed with stirring at room temperature overnight. After the reaction was completed, the reaction was quenched with water, and the aqueous phase was extracted three times with dichloromethane (15mL). The combined organic phase was first washed with saturated aqueous sodium bicarbonate (10mL), then washed with saturated saline (20mL), and the solvent was evaporated to dryness under reduced pressure to obtain crude product 2 (820mg, 80%), which was used directly in the next reaction. MS m / z: C 14 H 21 O5S, [M+H] + Theoretical: 301.10, Actual: 301.2.
[0387] [ka] Compound 3 (239 mg, 1.22 mmol) was dissolved in dimethylformamide (DMF, 10 mL), and a solution of NaH (60% dissolved in mineral oil, 93 mg, 2.33 mmol) was added in an ice bath. The reaction was carried out with stirring for 30 min. Compound 2 (350 mg, 1.16 mmol) was then added dropwise. After the addition was completed, the reaction was carried out with stirring at 60°C for 5 h. After the reaction was completed, water was added to quench the reaction. The aqueous phase was extracted three times with ethyl acetate (15 mL). The combined organic phase was first washed three times with water (10 mL), and then washed with saturated saline (10 mL). The solvent was then evaporated to dryness under reduced pressure, and the mixture was analyzed by reversed-phase preparative HPLC (C 18 (Conditions: 5%-50% (A: HO, B: CHCN), flow rate: 70 mL / min) and freeze-drying to give 220 mg of compound 4. MS m / z: C 19 H 21 N5O3Na, [M+Na] + Theoretical: 390.16, Actual: 390.3.
[0388] [ka] Compound 4 (1.50 g, 4.08 mmol) was dissolved in 20 mL of a mixture of acetic acid and water (4:1) at room temperature and stirred at 60 °C for 30 min. After the reaction was completed, the solvent was evaporated to dryness under reduced pressure and the resulting mixture was analyzed by reverse phase preparative HPLC (C 18 (Conditions: 5%-25% (A: HO, B: CHCN), flow rate: 70 mL / min) and freeze-drying to give 1.10 g of compound 5. MS m / z: C 16 H 18 N5O3, [M+H] + Theoretical: 328.13, Actual: 328.4.
[0389] [ka] Compound 5 (1.00 g, 3.05 mmol) was dissolved in pyridine (Py, 10 mL), and a solution of 4,4'-dimethoxytrityl chloride (DMTrCl, 1.50 g, 4.58 mmol) in pyridine (5 mL) was added dropwise in an ice bath. After the addition was completed, the reaction was allowed to proceed with stirring at room temperature overnight. After the reaction was completed, the reaction was quenched with water, and the solvent was evaporated to dryness under reduced pressure. The reaction was then analyzed by reverse phase preparative HPLC (C 18 (Conditions: 5%-80% (A: HO, B: CHCN), flow rate: 70 mL / min) and freeze-drying to give 1.00 g of compound 6. MS m / z: C 37 H 36 N5O5, [MH] + Theoretical: 630.26, Found: 630.5. Racemic compound 6 was resolved by chiral column (Daicel CHIRALPAK® IE 250 mm×4.6 mm, 5 μm, A: n-hexane, B: ethanol) to give 410 mg of 6A(−) and 435 mg of 6B(+).
[0390] [ka] Compound 6A(-) (200 mg, 0.32 mmol), tetrazolium (11 mg, 0.16 mmol), N-methylimidazole (5 mg, 0.06 mmol), and 3A molecular sieves (500 mg) were dissolved in 10 mL of acetonitrile, and compound 7 (144 mg, 0.48 mmol) was added at room temperature and stirred at room temperature overnight. After the reaction was completed, the molecular sieves were removed by filtration, dichloromethane (30 mL) was added, and the mixture was washed three times with saturated aqueous sodium bicarbonate solution (10 mL), and further washed with saturated saline (20 mL). The filtrate was concentrated and dried, and then purified by reverse phase preparative HPLC (C 18 (Conditions: 5% to 100% (A: water, B: CH3CN), flow rate: 70 mL / min) and freeze-drying to obtain 200 mg of compound 1-1a. MS m / z: C 40 H 39 N6O7P, [M-Diisopropyl+OH] +Theory: 747.26, actual measurement: 747.6. 1H NMR (400 MHz, acetonitrile-d3) δ 7.56, 7.54(2s, 1H), 7.36-7.27(m, 2H), 7.24-7.21(m, 7H), 6.83-6.80(m, 4H), 4.12-4.10(m, 2H), 3.75-3.68(m, 10H), 3.20-2.80(m, 2H), 2.68-2.54(m, 4H), 1.22-1.04(m, 18H).
[0391] [ka] Compound 6B(+) (200 mg, 0.32 mmol), tetrazolium (11 mg, 0.16 mmol), N-methylimidazole (5 mg, 0.06 mmol), and 3A molecular sieves (500 mg) were dissolved in 10 mL of acetonitrile, and compound 7 (144 mg, 0.48 mmol) was added at room temperature and stirred at room temperature overnight. After the reaction was completed, the molecular sieves were removed by filtration, dichloromethane (30 mL) was added, and the mixture was washed three times with saturated aqueous sodium bicarbonate solution (10 mL), and then with saturated saline (20 mL). The filtrate was concentrated and dried, and then purified by reverse phase preparative HPLC (C 18 (Conditions: 5% to 100% (A: water, B: CH3CN), flow rate: 70 mL / min) and freeze-drying to obtain 200 mg of compound 1-1b. MS m / z: C 40 H 39 N6O7P, [M-Diisopropyl+OH] + Theoretical: 747.26, Actual: 747.5.
[0392] 1.2 Synthesis of Compound 1-6a [ka] Compound 1 (10 g, 68.404 mmol), compound 2 (15 g, 62.186 mmol) and triphenylphosphine (32.62 g, 124.371 mmol) were dissolved in anhydrous THF (30 mL), and DIAD (24.656 mL, 124.371 mmol) was slowly added dropwise at 0 ° C. The reaction solution was reacted at 25 ° C. for 12 h, and LCMS showed that the reaction was complete. The reaction solution was extracted with ethyl acetate (200 mL) and water (200 mL), the organic phase was dried, and the filtrate was concentrated, and the obtained residue was purified by normal phase column (DCM / MeOH = 10 / 1) to obtain the target product 3 (20 g).
[0393] [ka] Compound 3 (20 g, 28.585 mmol) was dissolved in acetic acid (24 mL, 426.016 mmol) and H2O (12 mL) and stirred at 60 °C for 1 h. The reaction was then concentrated to dryness, THF (12 mL) and H2O (12 mL) were added, and the mixture was stirred at 80 °C for 7 h. LCMS showed the reaction was complete. The reaction was extracted with ethyl acetate (200 mL) and water (100 mL), and solid sodium carbonate was added to the aqueous phase until a large amount of solid precipitated in the aqueous phase. The solid was filtered, washed with water, and the filter cake was dried by oil pump to obtain the target compound 5 (9 g).
[0394] [ka] Under nitrogen gas protection, compound 5 (6.8 g, 18.581 mmol) was dissolved in pyridine (80 mL), and TMSCl (14.250 mL, 111.489 mmol) was added slowly at 0 °C, and stirred for 2 h. Then, isobutyryl chloride (2.044 mL, 19.511 mmol) was added at 0 °C, and stirred at 25 °C for 1 h, and LCMS showed that the reaction was complete. After extraction with dichloromethane (200 mL) and water (200 mL), and the organic phase was concentrated and dried, the sample was mixed and purified by normal phase column (DCM:MeOH = 10:1), and a peak was obtained at 4.8%) to obtain yellow oily compound 6 (12 g).
[0395] [ka] Under nitrogen gas protection, compound 6 (5.5 g, 12.392 mmol) was dissolved in pyridine (30 mL), molecular sieve 4A 1 / 16 (7 g, 12.392 mmol) was added, and then DMTrCl (5.04 g, 14.870 mmol) solid was added in several portions at 0 ° C., and the reaction was carried out at 25 ° C. for 2 h, and TLC (PE: EtOAc = 1: 1, Rf = 0.69) showed that the reaction was already completed. The reaction solution was treated together with TJN200879-040-P1. The reaction solution was extracted with ethyl acetate (200 mL) and water (200 mL), and the organic phase was concentrated and dried, and then the sample was mixed and purified with a normal phase column (PE: EtOAc was applied to the column, and a peak was obtained at 84%) to obtain a yellow oily compound 7 (12 g).
[0396] [ka] Compound 7 (12 g, 15.389 mmol) was dissolved in EtOAc (140 mL), and wet palladium carbon Pd / C (7 g, 15.389 mmol) was added, and the reaction solution was reacted at 25° C. under hydrogen gas (15 Psi) for 2 h. TLC (PE: EtOAc = 0: 1, Rf = 0.09) showed that the reaction was already completed. The reaction solution was filtered, and the filter cake was washed with ethyl acetate (30 mL) three times, and the filtrate was collected. The filtrate was concentrated and dried, and then 50 mL of dichloromethane and 2 mL of triethylamine were added to mix the sample, and the mixture was purified by normal phase column (DCM: MeOH = 10: 1, column, 0.5% peak), to obtain 9 g (yellow foamy solid), and the obtained racemic compound was separated by SFC to obtain the product target compound 7A (-) (3.9 g) and target compound 7B (+) (3.8 g).
[0397] [ka] Compound 7A(-) (3.30g, 5.40mmol), tetrazolium (190mg, 2.70mmol), 1-methylimidazole (90mg, 1.10mmol), 3A molecular sieve (500mg) were dissolved in 30mL of acetonitrile, and compound 8 (2.50g, 8.10mmol) was added at room temperature and stirred at room temperature for 2h. After the reaction was completed, the molecular sieve was filtered off, washed with DCM (150mL), saturated aqueous sodium bicarbonate (30mL x 3), and further washed with saturated saline (30mL), and the filtrate was concentrated and dried, and then passed through reverse phase preparative HPLC (C18, conditions: 5%-100% (A: water, B: CH3CN), flow rate: 70mL / min) and lyophilized to obtain 1-6a (2.9g, 66%). MS m / z: C43H55N7O7P [M+H]+, theoretical: 812.38, measured: 812.5. 1H NMR (400 MHz, acetonitrile-d3)δ 7.56, 7.54(2s, 1H), 7.36-7.27(m, 2H), 7.24-7.21(m, 7H), 6.83-6.80(m, 4H), 4.12-4.10(m, 2H), 3.75-3.68(m, 10H), 3.20-2.80(m, 2H), 2.68-2.54(m, 4H), 1.22-1.04(m, 18H).
[0398] 1.3 Synthesis of Compound 1-7a [ka] Under nitrogen gas protection, compound 1 (5g, 23.1272mmol), compound 2 (6.76g, 46.254mmol) and triphenylphosphine (7.28g, 27.753mmol) were dissolved in 30mL of dioxane, and DEAD (5.502mL, 27.753mmol) was slowly added dropwise at 0℃. After the addition was completed, the reaction was gradually heated to 25℃ and continued to react for 1h. The reaction solution was extracted with 100mL of H2O and 100mL of EtOAc, the organic phase was combined, dried, filtered and concentrated, and the sample was mixed and applied to a column, purified by normal phase column (PE: EtOAc = 1:1, applied to the column, and the target product (4g) was obtained.
[0399] [ka] Compound 3 (3.3 g) was dissolved in HOAc (16 mL) and HO (4 mL), heated in an oil bath at 60 °C for 0.5 h, concentrated to dryness, and the residue was purified by normal phase column chromatography (PE: EtOAc = 0:1) to give the target product 4 (3 g).
[0400] [ka] Compound 4 (3 g, 8.873 mmol) was dissolved in 5 mL of pyridine and 10 mL of DMTrCl (3.91 g, 11.535 mmol) was slowly added dropwise at 0° C. under nitrogen gas protection. After the addition was complete, the reaction was warmed to 25° C. and allowed to react for 1 h. The reaction was extracted with 50 mL of water and 100 mL of ethyl acetate. The aqueous phase was further extracted three times with 100 mL of ethyl acetate, and the organic phases were combined, dried, filtered, and concentrated and purified by normal phase column (PE:EtOAc=2:1). The target product 5 (4 g) was obtained.
[0401] [ka] Compound 5 (4 g, 5.769 mmol) was dissolved in methanol (10 mL), and saturated NH3 methanol solution (40 mL) was added and reacted at 0 °C for 6 h. The reaction solution was concentrated to dryness and purified by normal phase column (PE: EtOAc = 0: 1) to obtain 2.4 g of racemic compound, which was separated by SFC to obtain target product 6A (750 mg, 100% purity) and target product 6B (400 mg, 99.16% purity).
[0402] [ka] Compound 6A(-) (700 mg, 1.40 mmol), tetrazolium (50 mg, 0.70 mmol), 1-methylimidazole (23 mg, 0.28 mmol), and 3A molecular sieves (500 mg) were dissolved in 10 mL of acetonitrile, and compound 7 (630 mg, 2.10 mmol) was added at room temperature and stirred at room temperature for 2 h. After the reaction was completed, the molecular sieves were filtered off, and washed with DCM (50 mL), saturated aqueous sodium bicarbonate (10 mL x 3), and further washed with saturated saline (20 mL). The filtrate was concentrated and dried, and then passed through reverse phase preparative HPLC (C18, conditions: 5% to 100% (A: water, B: CH3CN), flow rate: 70 mL / min) and lyophilized to obtain 1-7a (700 mg, 72%). MS m / z: C38H47N4O7PNa[M+Na]+, theoretical: 725.32, observed: 725.5.
[0403] 1.4 Synthesis of Compound 1-8a [ka] Compound 1 (8.5 g, 76.508 mmol) and compound 2 (30.64 g, 91.809 mmol) were dissolved in DMF (150 mL), and CS2CO3 (29.91 g, 91.809 mmol) was added, and the reaction was reacted under nitrogen gas protection at 90 °C for 12 h. The reaction was detected to be complete by LCMS. The reaction solution was filtered, concentrated and dried by oil pump, and purified by normal phase column separation (80 g, DCM / MeOH = 10 / 1 ~ 5 / 1) to obtain the target product 3 (13.5 g, 80% purity).
[0404] [ka] Compound 3 (10.5 g, 35.105 mmol) was dissolved in pyridine (65 mL) and CH3CN (65 mL), and BzCl (4.894 mL, 42.126 mmol) was added dropwise to the solution and reacted at 25 ° C for 2 h. LCMS detected the completion of the reaction of most of the raw materials, and the mixture was quenched by adding H2O (100 mL), extracted with EtOAc (100 mL × 3), concentrated and dried, separated by column (combined with TJN200872-101) and purified (80 g, PE / EtOAc = 10 / 1 to 0 / 1, DCM / MeOH = 10 / 1) to obtain the target product 4 (14 g, 90% purity).
[0405] [ka] Compound 4 (14g, 36.694mmol) was dissolved in HOAc (56mL, 314.796mmol) and HO (14mL) and reacted at 60℃ for 2h, LCMS showed the reaction was complete. It was concentrated by oil pump and separated by normal phase column (40g, DCM / MeOH=1 / 0~5 / 1) to give the target product 5 (8.4g, 90% purity & 2.4g, 80% purity).
[0406] [ka] Compound 5 (7.4g, 21.957mmol), DMAP (0.54g, 4.391mmol), molecular sieve 4A (11.1g, 2.967mmol) were dissolved in pyridine (60mL), stirred in ice bath for 10min, then DMTrCl (8.93g, 26.348mmol) was added and reacted with stirring for 1.8h, LCMS showed that about 19% of the raw material remained and about 60% of the target was detected by MS. (TJN200872-105&106) and purified together. The reaction mixture was added with HO (50 mL), extracted with DCM (50 mL × 3), dried, concentrated to dryness, and separated by column (120 g, PE / (EA:DCM:TEA = 1:1:0.05) = 1 / 0 to 0 / 1 to DCM / MeOH = 10 / 1) to obtain yellow solid compound 6 (11 g, 89% purity, TJN200872-105 & 106 & 107), and the raw material (3.0 g, 70% purity) was recovered.
[0407] [ka] Compound 6 (15 g, 22.041 mmol) was separated by SFC (DAICEL CHIRALPAK AD (250 mm × 50 mm, 10 μm), 0.1% NH3HO EtOH, B: 45% to 45%, 200 mL / min) to give target product 6A (5.33 g, 94.29% purity), target product 6B (6.14 g, 97.91% purity), and 1.0 g of compound 6 was recovered.
[0408] [ka] Compound 6B(-) (5.4g, 8.92mmol), tetrazolium (312mg, 4.46mmol), 1-methylimidazole (146mg, 1.78mmol), 3A molecular sieve (500mg) were dissolved in 40mL of acetonitrile, and compound 7 (4g, 13.4mmol) was added at room temperature and stirred at room temperature for 2h. After the reaction was completed, the molecular sieve was filtered off, washed with DCM (200mL), saturated aqueous sodium bicarbonate (30mL x 3), and further washed with saturated saline (50mL), and the filtrate was concentrated and dried, and then passed through reverse phase preparative HPLC (C18, conditions: 5%-100% (A: water, B: CH3CN), flow rate: 70mL / min) and lyophilized to obtain 1-8a (5.8g, 80%). MS m / z: C45H51N5O7P, [M+H]+, theoretical: 804.36, measured: 804.4.
[0409] Example 2. Synthesis of siRNA The synthesis of siRNA is the same as that of the conventional phosphoramidite solid-phase synthesis method. When synthesizing the 7-position modified nucleotide of the AS chain 5', the parent sequence original nucleotide was replaced with the above synthesized phosphoramidite monomer. The synthesis process is briefly described below. Starting with the general-purpose CPG vector, nucleoside phosphoramidite monomers were linked one by one by the synthesis program in the Dr. Oligo48 synthesizer (Biolytic). Except for the 7-position nucleoside phosphoramidite monomer of the AS chain 5' described above, other nucleoside monomer raw materials such as 2'-F RNA and 2'-O-methyl RNA were purchased from Shanghai Jiaowei or Suzhou Jima. 5-Ethylthio-1H-tetrazole (ETT) was employed as the activator (0.6 M in acetonitrile), a 0.22 M solution of PADS in a 1:1 volume ratio of acetonitrile and trimethylpyridine (Suzhou Cortex) was used as the curing reagent, and an iodopyridine / water solution (Cortex) was used as the oxidizing agent.
[0410] After the solid-phase synthesis was completed, the oligoribonucleotides were dissolved from the solid support and soaked in a 3:1 solution of 28% aqueous ammonia and ethanol at 50°C for 16h. After centrifugation, the supernatant was transferred to another centrifuge tube, concentrated and evaporated to dryness, and purified by C18 reversed-phase chromatography using a mobile phase of 0.1 M TEAA and acetonitrile, and 3% trifluoroacetic acid solution to remove DMTr. The target oligonucleotides were collected, lyophilized, and identified as the target products by LC-MS and quantified by UV (260 nm).
[0411] The resulting single-stranded oligonucleotides were complementarily paired and annealed in an equimolar ratio, and the resulting double-stranded siRNA was dissolved in 1×PBS and adjusted to the concentration required for the experiment for use.
[0412] Example 3. psiCHECK Activity Screening Experiments The synthesis of the siRNA samples was as described above, and the plasmids were
number
[0413] [Table 1] Experimental steps: seed the cells on plates and transfect the cells, of which the specific preparation amount of the transfection complex is as shown in Table 2.
[0414] [Table 2]
[0415] According to Table 3, the working solution was diluted to different concentrations according to the needs of different experiments and prepared immediately before use. After 24 h transfection, the detection was performed according to the experimental procedure of the Dual-Glo® Luciferase Assay System detection reagent kit.
[0416] Calculate the relative value Ratio = Ren / Fir (Renillus / Firefly ratio) Inhibition rate 1-(Ratio+siRNA / reporter gene)×100%=inhibition rate (%) was calculated. In the present disclosure, excess activity % (also referred to as mRNA excess expression % or mRNA excess expression ratio) = 100% - inhibition rate (%).
[0417] [Table 3]
[0418] Example 4. On-target and off-target activity experiments of siRNAs containing different chemical modifications The compound of Example 1 was used to synthesize siRNA according to the method of Example 2, and the on-target activity and off-target activity of each siRNA were verified according to the method of Example 3, in which each siRNA adopted the same sense strand, and the 7th position of the 5' end of the antisense strand was the following modified nucleotide / chemical modification, respectively: [ka] Among them, the nucleotide synthesized using 2-hydroxymethyl-1,3-propanediol as the starting material is defined as hmpNA. (+)hmpNA(A) is obtained by solid-phase synthesis from the nucleoside phosphoramidite monomer 1-1b in Example 1.1, and has the absolute configuration (S)-hmpNA(A); (-)hmpNA(A) is obtained by solid-phase synthesis from the nucleoside phosphoramidite monomer 1-1a in Example 1.1, and has the absolute configuration (R)-hmpNA(A); Similarly, the base types of hmpNA were substituted and the following structures were obtained by solid phase synthesis and the absolute configurations were confirmed: (+)hmpNA(G) has the absolute configuration of (S)-hmpNA(G), (-)hmpNA(G) has the absolute configuration of (R)-hmpNA(G); (+)hmpNA(C) has the absolute configuration of (S)-hmpNA(C); (-)hmpNA(C) has the absolute configuration of (R)-hmpNA(C); (+)hmpNA(U) has the absolute configuration of (R)-hmpNA(U), (-)hmpNA(U) has the absolute configuration of (S)-hmpNA(U), The absolute configurations of (S)-hmpNA(G), (R)-hmpNA(G), (S)-hmpNA(C), (R)-hmpNA(C), (S)-hmpNA(U) and (R)-hmpNA(U) were confirmed by X-Ray diffraction from their intermediates or derivatives.
[0419] The structure of the intermediate or derivative is as follows:
[0420] [ka] TJ-NA067: The detected crystal is a colorless block (0.30 mm3 × 0.10 mm3 × 0.04 mm3) belonging to the monoclinic P21 space group. Cell parameters a = 16.0496(5) Å, b = 4.86260(10) Å, c = 16.4686(5) Å, α = 90°, β = 118.015(4)°, γ = 90°, V = 1134.65(7) Å3, Z = 4. Calculated density Dc = 1.389 g / cm3, number of electrons in the unit cell F(000) = 504.0, linear absorption coefficient of the unit cell μ(Cu Kα) = 0.840 mm-1, diffraction experiment temperature T = 150.00(11) K.
[0421] [ka] 6A(+): The detected crystal is a colorless block (0.30 mm3 × 0.20 mm3 × 0.10 mm3) belonging to the monoclinic P21 space group. Cell parameters a = 22.6688(7) Å, b = 8.5595(2) Å, c = 23.3578(5) Å, α = 90°, β = 113.876(3)°, γ = 90°, V = 4144.3(2) Å3, Z = 2. Calculated density Dc = 0.999 g / cm3, number of electrons in the unit cell F(000) = 1318.0, linear absorption coefficient of the unit cell μ(Cu Kα) = 0.570 mm-1, diffraction experiment temperature T = 100.01(18) K.
[0422] [ka] TJ-NA048: The detected crystal is colorless and needle-like (0.30 mm3 × 0.04 mm3 × 0.04 mm3) and belongs to the monoclinic P1 space group. Cell parameters a = 7.6165(4) Å, b = 11.3423(5) Å, c = 17.3991(8) Å, α = 85.007(4)°, β = 88.052(4)°, γ = 70.532(4)°, V = 1411.75(12) Å3, Z = 2. Calculated density Dc = 1.366 g / cm3, number of electrons in the unit cell F(000) = 620.0, linear absorption coefficient of the unit cell μ(Cu Kα) = 0.856 mm-1, diffraction experiment temperature T = 150.00(13) K.
[0423] [ka] TJ-NA092: The detected crystal is colorless and prismatic (0.30 mm3 × 0.10 mm3 × 0.10 mm3) and belongs to the monoclinic P1 space group. Cell parameters a = 5.17960(10) Å, b = 8.0667(2) Å, c = 12.4077(2) Å, α = 93.146(2)°, β = 101.266(2)°, γ = 96.134(2)°, V = 503.993(18) Å3, Z = 2. Calculated density Dc = 1.412 g / cm3, number of electrons in the unit cell F(000) = 228.0, linear absorption coefficient of the unit cell μ(Cu Kα) = 0.945 mm-1, diffraction experiment temperature T = 100.00(10) K.
[0424] Example 5. Sequence-dependent experiments of siRNAs containing different chemical modifications The experimental compounds of the present disclosure were tested in several different sequences. Using siRNAs targeting different gene mRNAs, (+)hmpNA(A), (-)hmpNA(A) and GNA(A) compounds as control were used to modify the 5'-end 7th position of AS chain (sequences are shown in Table 4-1 and Table 4-2).
[0425] [Table 4] [Table 5-1] [Table 5-2] The results of the on-target activity experiments are shown in Table 5. (A) shows obvious sequence dependency, and the on-target activity of different sequences is obviously different. The experimental compounds according to the present disclosure do not show obvious sequence dependency, and have stronger general applicability.
[0426] [Table 6] The experimental results of off-target activity can be seen in Table 6, which shows that the experimental compounds of the present disclosure clearly reduce the off-target activity of siRNA compared to the parent sequence.
[0427] [Table 7-1] [Table 7-2]
[0428] Example 6. Evaluation of different modifications at positions 9 and 10 of the AS chain This experiment examined the inhibitory efficiency of siRNA complexes or dsRNAs modified with 2'-fluoro at different sites of the present disclosure on the expression level of target gene mRNA in vivo.
[0429] Male 6-8 week old C57BL / 6 mice were randomly divided into groups, with a total of 6 mice per group, 3 mice per time point, and mice in each group were administered with the test complex (2 pieces, TRD007047 and TRD006870), the comparative complex (TRD002218) and PBS, respectively. All animals were administered a single dose by subcutaneous injection, with the dosage calculated according to body weight, and the dosage of siRNA complex or dsRNA (in terms of siRNA amount) was 1 mg / kg, and the administration volume was 5 mL / kg. Seven days after administration, the mice were sacrificed, and the livers were collected and preserved with RNA later (Sigma Aldrich). Then, the liver tissue was homogenized with a tissue homogenizer, and the liver tissue total RNA was extracted and obtained with a tissue RNA extraction reagent kit (Fanzhi Medical Technology, FG0412) according to the operation steps described in the instruction manual. The total RNA was reverse transcribed into cDNA, and the expression level of TTR mRNA in liver tissue was detected by real-time fluorescent quantitative PCR. In this fluorescent quantitative PCR, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was used as an internal reference gene, and the expression levels of TTR and GAPDH mRNA were detected by Taqman probe primers for TTR and GAPDH, respectively. The compound information is shown in Table 7, the grouping information of the experimental compounds in the mouse body is shown in Table 8, and the primers are shown in Table 9.
[0430] [Table 8]
[0431] The NAG1 structure is [ka] It was.
[0432] Compound NAG1 was prepared according to the method described in patent WO2021254360A1.
[0433] The L96 structure is [ka] It was. The control compound L96 was prepared according to the method described in patent WO2014025805A1.
[0434] [Table 9] [Table 10-1] [Table 10-2] After 28 days of administration, the inhibition efficiency of the siRNA complex or dsRNA modified with fluoro at different sites of the present disclosure on the expression level of target gene mRNA in vivo is shown in Table 10. With reference to the positive control TRD002218, the siRNA complex modified with fluoro at different sites showed higher inhibition of TTR mRNA expression than the reference positive control after 28 days of administration, and both of the two modification methods showed high inhibition efficiency and no significant difference, suggesting that the two modification methods at positions 9 and 10 of the AS chain can mediate more efficient inhibition efficiency.
[0435] [Table 11] The expression level of TTR mRNA was calculated according to the following equation.
[0436] TTR mRNA expression level = [(TTR mRNA expression level in test group / GAPDH mRNA expression level in test group) / (TTR mRNA expression level in control group / GAPDH mRNA expression level in control group)] × 100% Part 2. Targeting Ligands Example 7. Preparation of NAG0052, L96 Compounds NAG0024 and NAG0026 were purchased from Tianjin Yaoming Kangde New Drug Development Co., Ltd. Unless otherwise stated, all reagents used in the following examples are commercially available products.
[0437] (1) Synthesis of compound NAG0052 The starting material, compound 1, was purchased from Jiangsu Power Pharmaceutical Technology Co., Ltd.
[0438] [ka]
[0439] compound 2 At 0°C and under nitrogen gas protection, NaH (12.2 g, 304 mmol, 60% purity) was added in portions to a solution of compound 1 (12.3 mL, 101 mmol) in THF (300 mL). The mixture was stirred at 20°C for 1 h, then cooled to 0°C again, and benzyl bromide (36.3 mL, 304 mmol) was added dropwise to the system, and stirred at 20°C for 12 h. The reaction solution was quenched with H2O (100 mL) and extracted with EtOAc (200 mL x 2). The combined organic phase was washed with saturated brine (100 mL), dried over Na2SO4, filtered, and concentrated to obtain a residue that was separated by silica gel column chromatography to obtain the target compound 2 (20.0 g, 51.8 mmol, 51% yield). LCMS: t R = 2.615 and 2.820min in 30-90AB_7min_220&254_Shimadzu.lcm (Xtimate C18, 3um, 2.1*30mm), MS (ESI) m / z = 351.2 [M+Na] + . 1H NMR: (400 MHz, CDCl3) δ ppm 7.35-7.12 (m, 10H), 5.06-4.95 (m, 1H), 4.51-4.39 (m, 4H), 4.24-3.87 (m, 2H), 3.50-3.40 (m, 2H), 3.38-3.20 (m, 3H), 2.20-1.91 (m, 2H).
[0440] Compound 3 and Compound 4 At 20°C and nitrogen gas protection, TMSCN (13.5mL, 101mmol) was added in one portion to a solution of compound 2 (13.0g, 33.6mmol) in DCM (300mL), and then TMSOTf (9.14mL, 50.5mmol) in DCM (30mL) was added dropwise. The reaction solution was stirred at 20°C for 15h. After the reaction was completed, the system was quenched with saturated aqueous NaHCO3 (80mL) and extracted with DCM (150mL x 2). The combined organic phase was washed with saturated brine (80mL), dried over Na2SO4, filtered and concentrated, and separated by silica gel column chromatography to obtain the target compound 3 (3.30g, 9.18mmol, 27% yield) and pale yellow oily liquid compound 4 (8.50g, 9.18mmol, 70% yield).
[0441] compound 3 1 H NMR: (400 MHz, CDCl3) δ ppm 7.42-7.29 (m, 10H), 4.81 (t, J = 7.8 Hz, 1H), 4.65-4.49 (m, 4H), 4.30-4.21 (m, 2H), 3.65-3.57 (m, 1H), 3.57-3.49 (m, 1H), 2.49-2.40 (m, 2H).
[0442] compound 4 1H NMR: (400 MHz, CDCl3) δ ppm 7.42-7.26 (m, 10H), 4.93-4.87 (m, 1H), 4.65-4.48 (m, 4H), 4.43-4.38 (m, 1H), 4.21-4.17 (m, 1H), 3.79-3.70 (m, 1H), 3.54 (d, J = 4.0 Hz, 1H), 2.45-2.37 (m, 2H).
[0443] compound 5 At 0°C and nitrogen gas protection, a solution of compound 4 (3.00 g, 9.28 mmol) in THF (15 mL) was added dropwise to a solution of LiAlH4 (0.79 g, 20.9 mmol) in THF (15 mL), and after the completion of the addition, the system was reacted at 0°C for 1 h. The complete disappearance of the raw material was monitored by TLC (PE: EtOAc = 3: 1). Sodium sulfate decahydrate was gradually added to the reaction solution until no foaming occurred. The reaction solution was then filtered, and the filter cake was washed three times with dichloromethane (60 mL), after which the filtrate was collected and concentrated to dryness to obtain the target compound 5 (3.00 g, 90% yield). 1 H NMR: (400 MHz, DMSO-d6) δ ppm 7.40-7.14 (m, 10H), 4.54-4.38 (m, 4H), 4.06-3.99 (m, 2H), 3.91 (q, J = 6.4 Hz, 1H), 3.48-3.37 (m, 2H), 2.67-2.52 (m, 2H), 2.21-2.18 (m, 1H), 1.77-1.73 (m, 1H).
[0444] compound 6 Under nitrogen gas protection, compound 5 (3.00 g, 8.25 mmol) was dissolved in DCM (30 mL), TEA (3.44 mL, 24.7 mmol) and CbzCl (1.76 mL, 12.4 mmol) were added, and the mixture was reacted at 20 °C for 2 h. LCMS showed the reaction was complete. The reaction solution was extracted with dichloromethane (30 mL) and water (60 mL). The organic phase was washed three times with water (60 mL x 3), dried over anhydrous sodium sulfate, concentrated, and purified by normal phase column (PE: EtOAc = 1: 1) to give the target compound 6 (2.5 g, 90% yield). LCMS: t R = 0.810min in 5-95AB_1min, MS (ESI) m / z =462.2 [M+H] + . 1 H NMR: (400 MHz, CDCl3) δ ppm 7.39-7.29 (m, 15H), 5.35 (s, 1H), 5.15-5.01 (m, 2H), 4.72 (d, J = 6.0 Hz, 1H), 4.54-4.40 (m, 3H), 4.26 (s, 1H), 4.23-4.18 (m, 1H), 4.11-4.04 (m, 1H), 3.54-3.41 (m, 3H), 3.37-3.25 (m, 1H), 2.34-2.23 (m, 1H), 1.85-1.79 (m, 1H).
[0445] compound 7 Under nitrogen gas protection, compound 6 (2.00 g, 3.90 mmol) was dissolved in DCM (5 mL), and a solution of BCl3 in THF (1 M, 27.3 mL) was added at -78 °C and reacted for 1 h. The complete disappearance of the raw material was monitored by TLC (DCM:MeOH = 10:1). The reaction solution was quenched by adding methanol (20 mL) at -78 °C, concentrated, and purified by forward column (DCM:MeOH = 10:1) to obtain the target compound 7 (2.00 g, 60% yield). 1H NMR: (400 MHz, CD3OD) δ ppm 7.41-7.23 (m, 5H), 5.08 (s, 2H), 4.25-4.07 (m, 2H), 3.85-3.75 (m, 1H), 3.63-3.56 (m, 1H), 3.54-3.48 (m, 1H), 3.30-3.27 (m, 2H), 2.34-2.21 (m, 1H), 1.71-1.64 (m, 1H).
[0446] compound 8 Under nitrogen gas protection, compound 7 (0.50 g, 1.78 mmol) was dissolved in pyridine (5 mL), and 4A molecular sieves (500 mg) and DMTrCl (0.66 mL, 2.13 mmol) were added at 0 ° C., and then the temperature was raised to 20 ° C. and reacted for 1.5 h. The complete disappearance of the raw material was monitored by TLC (PE: EtOAc = 2: 1). The reaction solution was added to ethyl acetate (60 mL) and water (60 mL) for extraction, and the organic phase was washed three times with water (60 mL × 3), dried over anhydrous sodium sulfate, concentrated, and purified by forward column (PE: EtOAc = 1: 1) to obtain the target compound 8 (800 mg, yield 90%). 1 H NMR: (400 MHz, CDCl3) δ ppm 7.44 (d, J = 7.6 Hz, 2H), 7.37-7.23 (m, 11H), 7.22-7.15 (m, 1H), 6.84 (d, J = 8.8 Hz, 4H), 5.09 (s, 2H), 4.31-4.17 (m, 2H), 4.02-3.91 (m, 1H), 3.84-3.73 (m, 6H), 3.33 (s, 1H), 3.28 (s, 1H), 3.19-3.01 (m, 2H), 2.34-2.25 (m, 1H), 1.70-1.62 (m, 1H).
[0447] compound 9 Compound 8 (800 mg, 1.234 mmol) was dissolved in EtOAc (5 mL), Pd / C 10% (800 mg, 7.517 mmol) was added, and the reaction was run under H2 conditions (15 Psi) at 20°C for 1 h. LCMS showed that the reaction was already complete. The reaction was filtered, and the filter cake was washed with dichloromethane (100 mL) and methanol (100 mL) three times, concentrated, and separated through a reverse phase column to give compound 9 (300 mg, 54%). LCMS: t R = 2.586min in 10-80CD_3min MS (ESI) m / z = 450.2 [M+H] + .
[0448] compound 11 Compound 10 (435 mg, 1.780 mmol) was dissolved in DCM (10 mL), DIEA (0.441 mL, 2.67 mmol) and HATU (677 mg, 1.78 mmol) were added, and compound 9 (400 mg, 0.890 mmol) was further added and reacted at 20 ° C for 1 h. The reaction was monitored to be complete by TLC (DCM: MeOH = 10: 1). The reaction solution was extracted with dichloromethane (60 mL) and water (60 mL), and the organic phase was washed three times with water (60 mL × 3), dried over anhydrous sodium sulfate, concentrated, and purified by normal phase column (PE: EtOAc = 0: 1 was applied to the column, and the product peak appeared at 100%) to obtain the target compound 11 (600 mg, yield 90%). LCMS: t R = 2.745min in 30-90CD_3min, MS (ESI) m / z =698.4 [M+Na] + . 1H NMR: (400 MHz, CD3OD) δ ppm 7.46-7.38 (m, 2H), 7.35-7.24 (m, 6H), 7.22-7.16 (m, 1H), 6.90-6.78 (m, 4H), 4.29-4.21 (m, 2H), 4.02-3.95 (m, 1H), 3.77 (s, 6H), 3.66-3.62 (m, 3H), 3.41 (s, 1H), 3.18-3.04 (m, 2H), 2.36-2.17 (m, 5H), 1.71-1.50 (m, 5H), 1.39-1.25 (m, 14H).
[0449] compound 12 Compound 11 (600 mg, 0.799 mmol) was dissolved in THF (3 mL) and HO (1 mL), LiOH.HO (134 mg, 3.20 mmol) was added, and the mixture was allowed to react at 20 °C for 12 h. TLC (DCM:MeOH = 10:1) showed the reaction was complete. The reaction solution was concentrated to dryness, dissolved in water (5 mL) and methanol (5 mL), and purified by reverse phase column (HO:CHCN = 1:1, peak at about 35%) to give the target compound 12 (460 mg, 100% yield, lithium salt). LCMS: t R = 1.346min in 10-80CD_3min, MS (ESI) m / z =684.3 [M+Na] + . HPLC: R = 1.879min in 10-80CD_6min. 1H NMR: (400 MHz, CD3OD) δ ppm 7.47-7.39 (m, 2H), 7.35-7.24 (m, 6H), 7.22-7.15 (m, 1H), 6.91-6.79 (m, 4H), 4.31-4.18 (m, 2H), 4.02-3.95 (m, 1H), 3.78 (s, 6H), 3.44-3.33 (m, 2H), 3.18-3.04 (m, 2H), 2.35-2.27 (m, 1H), 2.24-2.10 (m, 4H), 1.70-1.51 (m, 5H), 1.31-1.23 (m, 12H).
[0450] compound 13 At room temperature and under nitrogen gas protection, compound NAG0024 (271 mg, 0.151 mmol) was dissolved in anhydrous THF (2 mL) and anhydrous DMF (4 mL), 3A molecular sieves were added, and compound 12 (100 mg, 0.151 mmol), HOBt (25 mg, 0.181 mmol), DCC (38 mg, 0.181 mmol) and DIEA (39 mg, 0.302 mmol) were added in sequence. The reaction solution was reacted at 45 ° C for 16 h, and after LC-MS showed that the reaction was complete, it was quenched by adding water and filtered. The filtrate was concentrated and then purified through a C18 reverse phase column (H2O / MeCN) to obtain compound 13 (210 mg, 57% yield).
[0451] Compound NAG0052 Compound 13 (230 mg, 0.094 mmol) was dissolved in pyridine (5 mL) at room temperature, molecular sieves were added, and DMAP (12 mg, 0.283 mmol) and succinic anhydride (28 mg, 0.283 mmol) were added. The mixture was stirred at 50 °C for 16 h under nitrogen gas protection. The reaction was detected as complete by LCMS, filtered, and concentrated to dryness. After purification by C18 reverse phase column, secondary purification was performed by preparative HPLC to obtain the target compound NAG0052 (123 mg, 0.048 mmol, 51% yield). MS(ESI)m / z=2535.3[M-1] - . Theory:2536.2. 1H NMR (400 MHz, acetonitrile-d3)δ 7.48-7.43(m, 2H), 7.37-7.12(m, 11H), 7.00-6.85(m, 10H), 6.66(s, 1H), 5.31(dd, J=3.4, 1.1 Hz, 3H), 5.20-5.13(m, 1H), 5.05(dd, J=11.3, 3.4 Hz, 3H), 4.56(d, J=8.5 Hz, 3H), 4.30(dd, J=7.7, 5.3 Hz, 1H), 4.18-3.93(m, 14H), 3.79(s, 10H), 3.65(q, J=4.7, 3.6 Hz, 13H), 3.56-3.07(m, 24H), 2.56(s, 6H), 2.37 (t, J=5.8 Hz, 10H), 2.17 (t, J=7.5 Hz, 9H), 2.02-1.96(m, 20H), 1.88(s, 8H), 1.82-1.73(m, 2H), 1.60(dt, J=15.0, 7.3 Hz, 16H), 1.27(s, 13H).
[0452] Example 8. Synthesis of siRNA complexes or dsRNA 1. Homemade vector-conjugated resin The compound NAG0052 (157 mg, 0.062 mmol) containing a carboxylic acid group was dissolved in anhydrous DMF (3 mL). After the substrate was completely dissolved, anhydrous acetonitrile (4 mL), DIEA (0.03 mL, 0.154 mmol, 2.5 eq) and HBTU (35 mg, 0.093 mmol, 1.5 eq) were added in sequence. After the reaction solution was mixed uniformly, macroporous aminomethyl resin (476 mg, blank loading 0.41 mmol / g, target loading 0.1 mmol / g) was further added. The reaction solution was placed in a shaker (temperature: 25° C., rotation speed: 200 rpm) and shaken overnight. The reaction solution was filtered, and the filter cake was washed with DCM and anhydrous acetonitrile in sequence, respectively, and the solid was collected and dried in vacuum overnight. The solid from the previous step was dispersed in anhydrous acetonitrile (5 mL), and pyridine (0.18 mL), DMAP (3 mg), NMI (0.12 mL), and CapB1 (2.68 mL) were added in that order. The reaction solution was placed in a shaker (temperature: 25 °C, rotation speed: 200 rpm) and shaken for 2 h. The reaction solution was filtered, the filter cake was washed with anhydrous acetonitrile, and the solid was collected and dried in vacuum overnight to obtain the vector-attached resin. The loading was measured to be 0.1 mmol / g.
[0453] 2. NAG0052 already linked to resin was linked to nucleoside monomers one by one starting from the resin in the 3'-5' direction according to the nucleotide sequence order. Linking to one nucleoside monomer involves four steps of deprotection, coupling, capping, and oxidation or sulfurization. The procedure was common in the art.
[0454] The siRNA complexes or dsRNAs prepared had the sense and antisense strands shown in Tables 11 and 12.
[0455] [Table 12] [Table 13-1] [Table 13-2] [Table 14] Among them, the complex TRD002218 was taken as the reference positive compound.
[0456] Example 9. Inhibition of target gene mRNA expression level in vivo by siRNA complex or dsRNA This experiment investigated the inhibitory efficiency of the siRNA complex or dsRNA of the present disclosure complexed with different structures on the expression level of target gene mRNA in vivo.
[0457] Male 6-8 week old C57BL / 6 mice were randomly assigned to groups with 6 mice in each group, 3 mice per time point, and mice in each group were administered the conjugate TRD007205 of the present disclosure, the reference positive nucleic acid ligand conjugate TRD002218, or PBS, respectively.
[0458] All animals were administered a single dose by subcutaneous injection, with the dosage calculated according to body weight, the dosage of siRNA complex or dsRNA (in terms of siRNA amount) was 1 mg / kg, and the administration volume was 5 mL / kg. After 7 and 28 days of administration, the mice were sacrificed, the livers were collected and preserved with RNA later (Sigma Aldrich), and then the liver tissue was homogenized with a tissue homogenizer, and total liver tissue RNA was extracted using a tissue RNA extraction reagent kit (Fanzhi Medical Technology, FG0412) according to the operation steps described in the instruction manual. The total RNA was reverse transcribed into cDNA, and the expression level of TTR mRNA in the liver tissue was detected by real-time fluorescent quantitative PCR. In the fluorescent quantitative PCR, the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was used as an internal reference gene, and the mRNA expression levels of TTR and GAPDH were detected by Taqman probe primers for TTR and GAPDH, respectively. The detection primer sequences were the same as those in Table 9.
[0459] [Table 15] The expression level of TTR mRNA was calculated according to the following equation.
[0460] TTR mRNA expression level = [(TTR mRNA expression level in test group / GAPDH mRNA expression level in test group) / (TTR mRNA expression level in control group / GAPDH mRNA expression level in control group)] × 100% After 7 and 28 days of administration, the inhibitory efficiencies of the siRNA complexes or dsRNAs of the present disclosure complexed with different structures on the expression levels of target gene mRNA in vivo are shown in Figures 1 and 2, respectively.
[0461] As can be seen from the results in Figure 1, after 7 days of administration, the inhibition of TTR mRNA expression by the complex TRD007205 had good effects, indicating that it could mediate more efficient delivery efficiency. As can be seen from Figure 2, after 28 days of administration, the inhibition effect of TRD007205 on the expression level of target gene mRNA was superior to that of TRD002218.
[0462] Example 10. Synthesis of siRNA-NAG0052 complex 1. Homemade vector-conjugated resin The specific procedure was the same as in Example 8.
[0463] 2. Starting with the resin with NAG0052, nucleoside monomers were linked one by one from the 3'-5' direction according to the nucleotide sequence order. Linking to one nucleoside monomer involves four steps: deprotection, coupling, capping, and oxidation or sulfurization.
[0464] Specifically, reference was made to the synthesis method in Example 2. The prepared siRNA complexes or dsRNAs had the sense and antisense strands shown in Table 15 and Table 16-1, Table 16-1.
[0465] [Table 16-1] [Table 16-2] [Table 17] [Table 18] Of these, the structures of (-)hmpNA(A), (-)hmpNA(G), (-)hmpNA(C), and (-)hmpNA(U) were as described in Example 4.
[0466] The structure of NAG0052' is [ka] It was.
[0467] Example 11. On-target activity of siRNA-NAG0052 complexes against different targets Table 17 was the positive control.
[0468] [Table 19] Among them, TRD007779 was prepared with reference to US11015201B.
[0469] The structure of GNA(A) is shown in Example 4, and the structure of GNA(t) is shown in [ka] It was.
[0470] The structure of L96 is [ka] It was.
[0471] In vitro molecular level simulated on-target activity screening was performed on the siRNA complexes or dsRNAs in Tables 15 and 17 using 11 concentration gradients in HEK293A cells.
[0472] An on-target sequence corresponding to siRNA was constructed in the AGT gene and inserted into the psiCHECK-2 plasmid. The plasmid contained Renilla luciferase gene and firefly luciferase gene. As a dual reporter gene system, the target sequence of siRNA was inserted into the 3'UTR region of Renilla luciferase gene, and the activity of siRNA against the target sequence could be reflected by detecting the expression status of Renilla luciferase calibrated with firefly luciferase, and the Dual-Luciferase Reporter Assay System (Promega, E2940) was used for detection.
[0473] HEK293A cells were cultured in DMEM high glucose medium containing 10% fetal bovine serum at 37°C and 5% CO2. 24 h before transfection, HEK293A cells were seeded into a 96-well plate and 8 × 10 3 Cells were seeded at a density of 100 μL medium in each well.
[0474] Cells were co-transfected with siRNA and the corresponding plasmids by Lipofectamine2000 (ThermoFisher, 11668019) according to the instruction manual, and 0.2 μL of Lipofectamine2000 was used for each well. The transfection amount of plasmid was 20 ng for each well, and for the on-target sequence plasmid, siRNA was set at a final concentration of 20 nM at the highest concentration point, and 11 concentration points were set in total, including 20 nM, 6.6667 nM, 2.2222 nM, 0.7407 nM, 0.2469 nM, 0.0823 nM, 0.0274 nM, 0.0091 nM, 0.0030 nM, 0.0010 nM, and 0.0003 nM, with a 3-fold gradient dilution. 24 h after transfection, on-target levels were detected by the Dual-Luciferase Reporter Assay System (Promega, E2940).
[0475] The experimental materials and equipment are detailed in Tables 18 and 19. The dilution process is shown in Table 20. The results are shown in Table 21.
[0476] The Psi-CHECK plasmid is
number
[0477] [Table 20] [Table 21] [Table 22] [Table 23-1] [Table 23-2] The above results demonstrated that the reference controls TRD007779, TRD008028, TRD008029, TRD008030, and TRD008031 had high levels of on-target inhibitory activity against the AGT gene in the psiCHECK system.
[0478] Example 12. Inhibition of human AGT in Huh7 cells - Inhibitory activity at seven concentration points Huh7 cell activity screening was performed on the siRNA complexes or dsRNAs in Tables 15 and 17 using 11 concentration gradients in Huh7 cells. The initial final concentration of each sample for transfection was 10 nM, with 5-fold gradient dilution, resulting in 7 concentration points.
[0479] Huh7 cells were cultured in DMEM high glucose medium containing 10% fetal bovine serum and incubated at 37°C with 5% CO2. 24 h before transfection, Huh7 cells were seeded into 96-well plates at a seeding density of 10,000 cells / well with 100 μL of medium in each well.
[0480] According to the product instruction manual, the samples were transfected using Lipofectamine RNAi MAX (ThermoFisher, 13778150), and the final concentrations of the samples transfected were 10nM, 2nM, 0.4nM, 0.08nM, 0.016nM, 0.0032nM, and 0.00064nM. After 24h treatment, the total cellular RNA was extracted using a high-throughput cellular RNA extraction reagent kit, and RNA reverse transcription experiments and quantitative real-time PCR detection were performed to measure the mRNA level of human AGT, and the mRNA level of human AGT was corrected by the level of the GAPDH internal reference gene.
[0481] The results were expressed as the percentage of excess over human AGT mRNA expression in cells treated with the control sample. IC 50 The results are shown in Table 22.
[0482] [Table 24] The results showed that TRD008028, TRD008029, TRD008030, and TRD008031 had good inhibitory activity against AGT in Huh7 cells.
[0483] Example 13. Inhibition of human AGT in Hep3B cells - seven concentration points inhibitory activity Activity screening was performed on the samples in Hep3B cells using a seven-point concentration gradient, with the initial final transfection concentration of each sample being 10 nM, and a five-fold gradient dilution with seven concentration points.
[0484] Hep3B cells were cultured in MEM medium containing 10% fetal bovine serum and incubated at 37°C with 5% CO2. 24 h before transfection, Hep3B cells were seeded into 96-well plates at a seeding density of 10,000 cells / well with 100 μL of medium in each well.
[0485] The samples were transfected using Lipofectamine RNAi MAX (ThermoFisher, 13778150) according to the product instruction manual, and the final concentrations of the samples transfected were 10nM, 2nM, 0.4nM, 0.08nM, 0.016nM, 0.0032nM, and 0.00064nM. After 24h treatment, the total cellular RNA was extracted using a high-throughput cellular RNA extraction reagent kit, and RNA reverse transcription experiments and quantitative real-time PCR detection were performed to measure the mRNA level of human AGT, and the mRNA level of human AGT was corrected by the level of the GAPDH internal reference gene.
[0486] The results were expressed as the percentage of excess over human AGT mRNA expression in cells treated with the control sample. IC 50 The results are shown in Table 23.
[0487] [Table 25] The results showed that TRD008028, TRD008029, TRD008030, and TRD008031 had good inhibitory activity against AGT in Hep3B cells. Part 3. Biological evaluation of targeted AGTs
[0488] Example 14. Design of human AGT siRNA 19 / 21nt siRNA was designed to target human AGT gene (NM_001384479.1) to meet the general rules of active siRNA. Unmodified sense and antisense strand sequences are detailed in Table 24 and Table 25, 7-position chemically modified antisense strands are detailed in Table 24, and modified sense and antisense strands are shown in Table 26, Table 27, and Table 28, and the present disclosure further provides sequences that do not contain thiophosphate groups in any of the sense and antisense strands in Table 26, Table 27, and Table 28.
[0489] [Table 26-1] [Table 26-2] When synthesizing the 7-position modified nucleotide of the 5' of the AS strand, the original nucleotide of the parent sequence was replaced with the phosphoramidite monomer synthesized in Example 1 or the phosphoramide monomer modified with a 2'-methoxy group. Among them, W' is [ka] or a tautomer-modified nucleotide, or a nucleotide modified with a 2'-methoxy group; In which M is O or S; B was selected from the bases corresponding to the 7th position of the 5' end of SEQ ID NO:7 to SEQ ID NO:12 in Table 24. For example, SEQ ID NO:13 corresponds to SEQ ID NO:7, and SEQ ID NO:17 corresponds to SEQ ID NO:11.
[0490] [Table 27-1] [Table 27-2] [Table 27-3] [Table 28-1] [Table 28-2] [Table 28-3] [Table 28-4] The NAG0052 structure is [ka] The L96 structure was [ka] It was.
[0491] [Table 29-1] [Table 29-2] [Table 29-3] [Table 30-1] [Table 30-2] [Table 30-3] The NAG0052 structure is [ka] It was.
[0492] Example 15. Inhibitory activity against AGT in human hepatoma cell line (Hep3B) In the human hepatoma cell line (Hep3B), two dose experiments were performed at 10 nM and 0.1 nM final duplex concentrations, and a single dose experiment was performed at 0.1 nM final duplex concentration. The experimental consumables are shown in Table 29.
[0493] 24 h prior to transfection, Hep3B cells were plated in a 96-well plate at approximately 20,000 cells / well with 100 μL of medium per well. During transfection, samples were transfected using Lipofectamine RNAi MAX (ThermoFisher, 13778150) according to the product instructions, and the final gradient concentration of sample transfection was 10 nM and / or 0.1 nM. After 24 hours of treatment, total cellular RNA was extracted using a high-throughput cellular RNA extraction reagent kit (FG0417-L / FG0418-XL, magnetic bead method), RNA reverse transcription experiment (Takara PrimeScript™ II 1st Strand cDNA Synthesis Kit (6210A)) and quantitative real-time PCR (Takara PrimeScript™ II 1st Strand cDNA Synthesis Kit (6210A) detection were performed, and the Taqman probe primer information was referred to Table 30. The human AGT mRNA level was measured and corrected by the GAPDH internal reference gene level.
[0494] After the Taqman probe Q-PCR detection experiment is completed, the corresponding Ct value is obtained according to the threshold automatically set by the system, and the expression of a certain gene can be relatively quantified by comparing the Ct values: the Ct comparison is to calculate the difference in gene expression by the difference value with the internal reference gene Ct value, and the difference is calculated by the difference value.-△△Ct Also called △△Ct = [(Ct experimental group target gene - Ct experimental group internal standard) - (Ct control group target gene - Ct control group internal standard)]. Inhibition rate (%) = (1 - excess target gene expression) x 100%.
[0495] [Table 31] [Table 32] The results are shown as the percentage excess of human AGT mRNA expression in control treated cells, and the IC 50 The results are shown in Table 31.
[0496] [Table 33] As can be seen from the data in Table 31, The growth inhibitory activity of TRD007716 against AGT at a low concentration of 0.1 nM was obviously superior to that of TRD007343, TRD007344, TRD007345, TRD007346, TRD007347, TRD007348, TRD007349, TRD007350, TRD007351, TRD007352, TRD007353, TRD007354, TRD0269 and TRD0270. Among them, the parent sequences of 14 sequences were the same as the parent sequence of TRD007716, i.e., TJR100299, shifted by n bases, and the modifications were all the same.
[0497] The proliferation inhibitory activity of TRD007770 against AGT at a low concentration of 0.1 nM was obviously superior to that of TRD007657, TRD007658, and TRD007659. Among them, the parent sequences of the three sequences were the same as the parent sequence of TRD007770, i.e., TJR100283, shifted by n bases, and the modifications were all the same.
[0498] The above results demonstrated that the sequences derived from TJR100299 and TJR100283 themselves have superior AGT expression inhibitory activity.
[0499] Example 16. Inhibition of AGT in human hepatoma cell line (Hep3B) - multi-point inhibitory activity Dose-response experiments were performed in a human hepatoma cell line (Hep3B) using a 7-concentration gradient.
[0500] 24h before transfection, Hep3B cells were plated in a 96-well plate at approximately 20,000 cells / well with 100μL of medium per well. During transfection, the samples were transfected using Lipofectamine RNAi MAX (ThermoFisher, 13778150) according to the product instructions, and the gradient final concentrations of the samples transfected were 10nM, 2nM, 0.4nM, 0.08nM, 0.016nM, 0.0032nM and 0.00064nM. After 24h treatment, total cellular RNA was extracted using a high-throughput cellular RNA extraction reagent kit, RNA reverse transcription experiment and quantitative real-time PCR detection were performed to measure the human mRNA level, and the human AGT mRNA level was corrected by the GAPDH internal reference gene level.
[0501] The results are shown as the percentage excess of human AGT mRNA expression in control treated cells, and the IC 50 The results are shown in Table 32. The experimental procedures were as described in Example 15.
[0502] [Table 34] As can be seen from the data in Table 32, The inhibitory activity of TRD007716, TRD007925, TJR100023, TJR100024 and TJR100104 against AGT was superior to that of TJR100025, and the inhibitory activity of TRD008029, TRD007920, TRD007770, TJR100101 and TJR100102 against AGT was superior to that of TJR100189, TJR100190, TJR100191, TJR100192, TJR100193 and TJR100167. The results showed that compared with the control sequence, the sequences of various different modifications derived from the parent sequence TJR100283, TJR100299 had superior inhibitory activity.
[0503] The inhibitory activity of TJR100283 against AGT is superior to those of TJR100286, TJR100290, TJR100291, TJR100292 and TJR100293, and the inhibitory activity of TJR100299 against AGT is superior to those of TJR100302, TJR100303, TJR100304, TJR100305, TJ100306, TJR100307 and TJR100 308, TJR100309, TJR100310, TJR100311, TJR100312 and TJR100313, and the inhibitory activity of TJR100320 against AGT was clearly superior to TJR100322, TJR100323, TJR100324, TJR100325, TJR100326, TJR100327 and TJR100328. The sequences of these samples were obtained by performing conversions such as the first base mutation and base shift at the 5' end on the three sequences of TJR100283, TJR100299 and TJR100320, respectively. The results showed that the three sequences themselves, namely TJR100283, TJR100299 and TJR100320, had better AGT inhibitory activity, and all of the base changes weakened the AGT inhibitory activity.
[0504] Example 17. Validation of psiCHECK on-target levels In HEK 293A cells, the samples were subjected to in vitro molecular level simulated off-target level screening using 11 concentration gradients, and the experimental results are shown in Table 34.
[0505] For the sample sequence, the corresponding on-target sequence was constructed, that is, the on-target plasmid (GSCM) of the sample target sequence was constructed and inserted into the psiCHECK plasmid containing Renilla luciferase gene and firefly luciferase gene. As a dual reporter gene system, the activity of the sample against the target sequence can be reflected by the detection of Renilla luciferase expression after firefly luciferase correction, and the Dual-Luciferase Reporter Assay System (Promega, E2940) was used for detection.
[0506] HEK 293A cells were cultured in DMEM high glucose medium containing 10% fetal bovine serum and incubated at 37°C with 5% CO2. 24 h prior to transfection, HEK 293A cells were seeded into 96-well plates at a seeding density of 8000 cells / well with 100 μL of medium in each well.
[0507] The cells were co-transfected with the samples and the corresponding plasmids using Lipofectamine2000 (ThermoFisher, 11668019) according to the instruction manual, and 0.2 μL of Lipofectamine2000 was used for each well. The transfection amount of the plasmid was 10 ng / well. For the on-target sequence plasmid, the sample was set to a final concentration of 20 nM at the highest concentration point, and 11 concentration points were set in total, including 20 nM, 6.667 nM, 2.222 nM, 0.741 nM, 0.247 nM, 0.082 nM, 0.0274 nM, 0.0091 nM, 0.0030 nM, 0.001 nM, and 0.0003 nM, with a 3-fold gradient dilution. The dilution method of the multi-concentration point samples was referred to Table 33. 24 h after transfection, off-target levels were detected using the Dual-Luciferase Reporter Assay System (Promega, E2940). Relative value Ratio = Ren / Fir was calculated, and inhibition rate 1-(Ratio+siRNA / reporter gene only) x 100% = inhibition rate (%) was calculated.
[0508] [Table 35] [Table 36] As the data shows, The inhibitory activity against AGT of TRD008029, TJR100053, TJR100101, TJR100102 and TRD008096-1 was superior to that of TJR100160, TJR100161, TJR100162 and TRD0321. Compared with the control sequence, various dsRNA or siRNA complexes derived from the TJR100283 parent sequence showed superior inhibitory activity.
[0509] The inhibitory activity against AGT of TJR100024, TJR100072, TJR100103 and TJR100104 was superior to that of TJR100025. It was shown that various dsRNA or siRNA complexes derived from the parent sequence of TJ100299 have superior inhibitory activity.
[0510] Example 18. Verification of AS and SS chain psiCHECK off-target levels In vitro molecular level simulated off-target level screening was performed in HEK 293A cells using 11 concentration gradients, and the experimental results are shown in Table 35.
[0511] The corresponding target plasmid construction rules are as follows:
[0512] The off-target sequence of the AS strand of each sample was designed, i.e., an off-target plasmid (GSSM) was constructed that is completely complementary to positions 1 to 8 of the 5' end of the antisense strand but does not completely match the bases at other positions, and the base mismatch correspondence rule is that A matches C and G matches T. To improve the detection sensitivity, an off-target plasmid GSSM-5hits was constructed, i.e., five identical GSSM sequences were linked by TTCC and inserted into the psiCHECK plasmid containing the Renilla luciferase gene and the firefly luciferase gene. As a dual reporter gene system, the target sequence was inserted into the 3'UTR region of the Renilla luciferase gene.
[0513] For the sense strand, an off-target plasmid (PSCM) that is completely complementary to the SS strand is constructed, and an off-target plasmid (PSSM) that is completely complementary to positions 1 to 8 of the 5' end of the sense strand but does not completely match the bases at other positions is constructed, and the base mismatch correspondence rule is that A matches C and G matches T. In order to improve the detection sensitivity, an off-target plasmid PSSM-5hits is constructed, that is, five identical PSSM sequences are linked by TTCC.
[0514] The activity against the target sequence can be reflected by the detection of Renilla luciferase expression after correction of firefly luciferase, and the Dual-Luciferase Reporter Assay System (Promega, E2940) was used for detection. The remaining experimental process was referred to Example 17.
[0515] [Table 37-1] [Table 37-2] The results showed that the listed samples had no or very little off-target risk.
[0516] Example 19. Inhibition of AGT in human hepatoma cell line (Huh7) - multi-concentration inhibitory activity Dose-response experiments were performed on siRNA using a 7-concentration gradient in a human hepatoma cell line (Huh7).
[0517] 24h before transfection, Huh7 cells were plated in a 96-well plate at approximately 20,000 cells / well with 100μL of medium per well. During transfection, the samples were transfected using Lipofectamine RNAiMAX (ThermoFisher, 13778150) according to the product instructions, and the gradient final concentrations of the samples transfected were 10nM, 2nM, 0.4nM, 0.08nM, 0.016nM, 0.0032nM and 0.00064nM. After 24h treatment, the high-throughput cell RNA extraction reagent kit was used to extract total cell RNA, RNA reverse transcription experiment and quantitative real-time PCR detection were performed to measure the human mRNA level, and the human AGT mRNA level was corrected by the GAPDH internal reference gene level.
[0518] The results are shown as the percentage excess of human AGT mRNA expression in control treated cells, and the IC 50 The results are shown in Table 36. The experimental procedures were as described in Example 12.
[0519] [Table 38] The inhibitory activity of the three sequences, TRD007920, TRD008096, and TJR100053, against AGT mRNA in Huh7 was superior to that of TJR100189, TJR100190, TJR100191, TJR100192, and TJR100193.
[0520] Example 20. Inhibitory activity of AGT in primary human hepatocytes (PHH) Dose-response experiments were performed in primary human hepatocytes (PHH) using 8- and 7-concentration gradients.
[0521] During transfection, the samples were transfected using Lipofectamine RNAiMAX (ThermoFisher, 13778150) according to the product instruction manual, and the gradient final concentrations of the samples transfected were 20nM, 6.67nM, 2.22nM, 0.74nM, 0.25nM, 0.082nM, 0.027nM and 0.009nM. In other groups, gradient concentrations of 10nM, 2nM, 0.4nM, 0.08nM, 0.016nM, 0.0032nM and 0.00064nM were used. RNAiMAX and samples diluted with Opti-MEM I were mixed uniformly in equal volumes, incubated at room temperature for 15min, and then added to a 96-well plate in a volume of 10μL / well, and then 90μL (6.7E5 cells / mL) of resuscitated cryopreserved PHH cell suspension was added to each well. 24 h after transfection, cells were harvested and total cellular RNA was extracted using RNeasy 96 Kit (Qiagen-74182). The reverse transcription reagent kit (Amane, KR106) was used to add random primers and reverse transcribed into cDNA according to the instructions. The AGT mRNA level in the samples was detected by qPCR method, and the mRNA level of human AGT was corrected by the GAPDH internal reference gene level.
[0522] The expression level of target AGT mRNA in each sample was calculated by the ΔΔCt relative quantification method. The target relative expression level was calculated as 2 -ΔΔCT The calculation formula was as follows:
[0523] ΔCT = target mean Ct value - internal reference gene mean Ct value ΔΔCT = ΔCT (treatment group) - ΔCT (control group) Target mRNA relative expression level = 2 -ΔΔCT IC was calculated using Graphpad Prism software (four parameter logistic equations). 50 The values were calculated and the results are shown in Table 37.
[0524] [Table 39] All sequences showed good inhibitory activity against AGT mRNA in PHHs.
[0525] Example 21. Inhibition of AGT in primary monkey hepatocytes (PCH) - multi-point inhibitory activity Dose-response experiments were performed on samples using a 7-concentration gradient in primary monkey hepatocytes (PCH).
[0526] During transfection, the samples were transfected using Lipofectamine RNAiMAX (ThermoFisher, 13778150) according to the product instruction manual, and the gradient final concentrations of the sample transfection were 10 nM, 2 nM, 0.4 nM, 0.08 nM, 0.016 nM, 0.0032 nM, and 0.00064 nM. RNAiMAX after dilution with Opti-MEM I and the samples were mixed uniformly in equal volumes, incubated at room temperature for 15 min, and then added to a 96-well plate in a volume of 10 μL / well, and then 90 μL (6.7E5 cells / mL) of resuscitated cryopreserved PCH cell suspension was added to each well. 24 h after transfection, the cells were collected, and the cellular total RNA was extracted using RNeasy 96 Kit (Qiagen-74182). Referring to the reverse transcription reagent kit (Tengen, KR106) instruction manual, random primers were added to reverse transcribe into cDNA. The AGT mRNA level in the samples was detected by qPCR method, and the monkey AGT mRNA level was normalized by the GAPDH internal reference gene level. The probe primer sequence information is shown in Table 38.
[0527] The expression level of target AGT mRNA in each sample was calculated by the ΔΔCt relative quantification method. The target relative expression level was calculated as 2 -ΔΔCT The calculation formula was as follows:
[0528] ΔCT = target mean Ct value - internal reference gene mean Ct value ΔΔCT = ΔCT (treatment group) - ΔCT (control group) Target mRNA relative expression level = 2 -ΔΔCT IC was calculated using Graphpad Prism software (four parameter logistic equations). 50 The values were calculated and the results are shown in Table 39.
[0529] [Table 40] [Table 41-1] [Table 41-2] The first seven sequences showed excellent inhibitory activity against AGT in PCH, and the activity of TJR100283 was obviously superior to that of TJR100292, TJR100293, and TJR100295. The TJR100283 sequence itself, its complex, or dsRNA showed very strong inhibitory activity against AGT.
Claims
1. siRNA comprising a sense strand and an antisense strand forming a double-stranded region, the sense strand comprises at least 15 consecutive nucleotides and differs from any one of SEQ ID NOs: 1, 2, 3, 4, 5, and 6 by no more than 3 nucleotides; the antisense strand comprises at least 15 consecutive nucleotides and has a difference of 3 nucleotides or less from any one of the nucleotide sequences of SEQ ID NOs: 7, 8, 9, 10, 11, and 12; The siRNA targets angiotensinogen.
2. the sense strand comprises at least 17 consecutive nucleotides of a nucleotide sequence selected from any one of SEQ ID NO:1 to SEQ ID NO:6; the antisense strand comprises at least 19 consecutive nucleotides of a nucleotide sequence selected from any one of SEQ ID NOs: 7 to 12; Preferably, the sense strand comprises a nucleotide sequence selected from any one of SEQ ID NO: 1 to SEQ ID NO: 6, Preferably, the antisense strand comprises a nucleotide sequence selected from any one of SEQ ID NO: 7 to SEQ ID NO:
12. The siRNA described in claim 1.
3. Group 1) a sense strand shown in SEQ ID NO: 1 and an antisense strand shown in SEQ ID NO: 7; Group 2) a sense strand shown in SEQ ID NO: 2 and an antisense strand shown in SEQ ID NO: 8; Group 3) a sense strand shown in SEQ ID NO: 3 and an antisense strand shown in SEQ ID NO: 9; Group 4) the sense strand shown in SEQ ID NO: 4 and the antisense strand shown in SEQ ID NO: 10; Group 5) the sense strand shown in SEQ ID NO:5 and the antisense strand shown in SEQ ID NO:11; Group 6) the sense strand shown in SEQ ID NO: 6 and the antisense strand shown in SEQ ID NO: 12; or any one of the groups selected therefrom; siRNA according to claim 1 or 2.
4. At least one nucleotide of the sense strand and / or the antisense strand is a modified nucleotide; siRNA according to any one of the preceding claims.
5. At least one nucleotide in positions 2 to 8 of the 5' end of the antisense strand is a modified nucleotide, said modified nucleotide is a nucleotide modified with a 2'-methoxy group, or The modified nucleotide comprises a chemical modification as shown in formula (I) or a tautomeric modification thereof, the chemical modification as shown in formula (I) being 【Chemistry 156】 Selected from B is independently selected from bases corresponding to positions 2 to 8 of the 5' end of the antisense strand; siRNA according to any one of the preceding claims.
6. The nucleotide at position 5, 6, or 7 of the 5' end of the antisense strand is - a nucleotide modified with a 2'-methoxy group, or - comprising a chemical modification according to formula (I) as defined in claim 5 or a tautomeric modification thereof, When the chemical modification shown in formula (I) or a tautomer modification thereof is at the 5-position of the 5'-terminus, B is a base at the 5-position of the 5'-terminus of the antisense strand; When the chemical modification shown in formula (I) or a tautomer modification thereof is at the 6-position of the 5'-terminus, B is a base at the 6-position of the 5'-terminus of the antisense strand; When the chemical modification shown in formula (I) or a tautomer modification thereof is at the 7-position of the 5'-terminus, B is the base at the 7-position of the 5'-terminus of the antisense strand; siRNA according to any one of the preceding claims.
7. three consecutive nucleotides of the sense strand are 2'-fluoro modified nucleotides; and / or In the 5' to 3' direction, the nucleotides at positions 2, 4, 6, 9, 12, 14, 16, and 18 of the antisense strand are each independently a 2'-fluoro modified nucleotide; or in the 5' to 3' direction, the nucleotides at positions 2, 4, 6, 10, 12, 14, 16, and 18 of the antisense strand are each independently a 2'-fluoro modified nucleotide; siRNA according to any one of the preceding claims.
8. The sense strand is 5'-N a N a N a N a N a N a N b N b N b N a N a N a N a N a N a N a N a N a N a -3', or, 5'-N a N a N a N a N b N a N b N b N b N a N a N a N a N a N a N a N a N a N a -3', Among them, N a is a nucleotide modified with a 2'-methoxy group, and N b is a 2'-fluoro modified nucleotide; siRNA according to any one of the preceding claims.
9. The antisense strand is 5'-N a 'N b 'N a 'N b 'N a 'N b 'W'N a 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N a 'N a '-3', or, 5'-N a 'N b 'N a 'N b 'N a 'N b 'W'N a 'N b 'N a 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N a 'N a '-3', Among them, N a ' is a nucleotide modified with a 2'-methoxy group, N b ' is a 2'-fluoro modified nucleotide, W' is a nucleotide modified with a 2'-methoxy group, or W' is a nucleotide having the chemical modification shown in formula (I) as defined in claim 5 or a tautomer modification thereof; siRNA according to any one of the preceding claims.
10. W' is 【Chemistry 157】 nucleotides containing modifications, wherein B is a base, and preferably B is selected from the base at the position corresponding to position 7 of the 5'-end of the antisense strand; The siRNA described in claim 9.
11. W' is selected from nucleotides modified with a 2'-methoxy group; The siRNA described in claim 10.
12. The sense strand comprises or is selected from any one of SEQ ID NOs: 135 to 162; The antisense strand comprises or is selected from any one of SEQ ID NOs: 189 to 216; siRNA according to any one of the preceding claims.
13. A double-stranded ribonucleic acid, The siRNA according to any one of claims 1 to 12, and a targeting ligand linked to the end of the siRNA, Preferably, the targeting ligand is linked to the 3' end of the sense strand of the siRNA. Double-stranded ribonucleic acid.
14. The targeting ligand comprises at least one targeting moiety; the targeting moieties are each independently selected from galactose, galactosamine, N-formyl-galactosamine, N-acetyl-galactosamine, N-propionyl-galactosamine, N-n-butyryl-galactosamine, and N-isobutyryl-galactosamine; Preferably, the targeting moiety is N-acetyl-galactosamine; More preferably, the targeting ligand comprises three identical or different targeting moieties. The double-stranded ribonucleic acid according to claim 13.
15. The targeting ligand is a compound represented by formula (II) or a pharma- ceutically acceptable salt thereof, wherein the formula (II) is 【Chemistry 158】 The double-stranded ribonucleic acid according to claim 14,
16. A double-stranded ribonucleic acid comprising a sense strand and an antisense strand forming a double-stranded region, The sense strand is selected from any one of SEQ ID NOs: 163 to 188; The antisense strand is selected from any one of SEQ ID NOs: 217 to 242; Preferably, the double-stranded ribonucleic acid is selected from TRD008096, TJR100053 or TJR100296; Double-stranded ribonucleic acid.
17. 1. A pharmaceutical composition comprising: The siRNA according to any one of claims 1 to 12 or the double-stranded ribonucleic acid according to any one of claims 13 to 16, and a pharma- ceutically acceptable vector. Pharmaceutical compositions.
18. 1. A method for inhibiting angiotensinogen gene expression, comprising: An effective amount or dose of The siRNA according to any one of claims 1 to 12, or The double-stranded ribonucleic acid according to any one of claims 13 to 16, or 20. A method comprising administering the pharmaceutical composition of claim 17.
19. 1. A method for treating and / or preventing a disease, comprising: Administering to a subject an effective amount or dose of the siRNA according to any one of claims 1 to 12, or the double-stranded ribonucleic acid according to any one of claims 13 to 16, or the pharmaceutical composition according to claim 17, Preferably, said disease is hypertension.
20. 1. A method for the internal delivery of siRNA or double-stranded ribonucleic acid to the liver, comprising: The siRNA or double-stranded ribonucleic acid inhibits angiotensinogen gene expression and / or replication, The method comprises administering to a subject the double-stranded ribonucleic acid according to any one of claims 13 to 16, or the pharmaceutical composition according to claim 17.
21. 1. A method for preparing siRNA or double stranded ribonucleic acid, comprising: A method comprising synthesizing an siRNA according to any one of claims 1 to 12 or a double-stranded ribonucleic acid according to any one of claims 13 to 16.
Citation Information
Patent Citations
Angiotensinogen (AGT) iRNA composition and its use
JP2017517511A
Compounds and methods for modulating angiotensinogen expression
JP2018530325A
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
JP2021522841A
Methods and compositions for treating an angiotensinogen- (AGT-) associated disorder
WO2021096763A1
Modified sirna with reduced off-target activity
WO2022028462A1
